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Introduction
A Introduction
A.1 Background
Glioblastoma multiforme (GBM) is the most common type of primary brain tumors in
adults (Wen and Kesari, 2008). Tumors classified into GBM make up the majority of
malignant  gliomas  (60-70%),  other  high-grade  gliomas  consist  of  anaplastic
astrocytomas  (10-15%),  anaplastic  oligodendrogliomas  (10%)  and  less  frequent
subtypes (Ostrom et al., 2014). GBM is more common in males compared to females
with an overall incident rate of 3-5/100,000 people per year. The overall median age
at time of diagnosis is 64 years (Wen and Kesari, 2008). 
The survival of the patients is poor and inversely correlated with age, ranging from a
median survival of 8.8 months in the group of patients younger than 50 to a survival
of  only 1.6 months in the group of  patients older than 80  (Ohgaki  and Kleihues,
2007).  In  the  early  2000s,  a  phase  II  study  showed  that  a  combination  of
radiotherapy and concomitant chemotherapy using temozolomide (TMZ) followed
by adjuvant TMZ therapy could increase the median survival to 16 months, whereby
patients under 50 years old and those who underwent surgery had the best survival
outcome (Stupp et al., 2002). The subsequent study by Stupp et al. (2005) led to the
current standard protocol of GBM treatment that consists of radiotherapy (60 Gray
(Gy) in 30x 2 Gy fractions) concomitantly with daily TMZ chemotherapy (75 mg/m2
per m2) for 42 days, followed by a maintenance TMZ treatment. Five years later, the
authors reported an overall survival of 27.2% at 2 years, 16% at 3 years versus a
respective survival of 10.9% and 4.4% with radiotherapy alone  (Stupp et al., 2005,
2009). 
Surgical  resection is generally performed prior radiochemotherapy except for  the
very elderly or with poor performance status (Wen and Kesari, 2008). It provides an
immediate mass effect relief for the patients and is used for pathological analysis of
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the tumor. Usually, gross total  resection of the contrast-enhancing mass, without
provoking  neurological  deterioration,  should  be  attained  (Delgado-López  and
Corrales-García,  2016). Aggressive extent of resection improves overall  survival of
the patients even at the highest levels of resection (Sanai et al., 2011). Although, if
gross total resection is not possible, even partial resection with thresholds of >70%
resection and  residual  tumor volume of  <5  cm3 could be associated with higher
survival  of  GBM  patients  (Chaichana  et  al.,  2014).  Despite  this  treatment,  even
complete resection is associated with recurrence of the tumor within 2 cm of the
resection margins  (Wallner et al., 1989). Even today, only complete removal of the
complete tumor was related with survival bonus (Quick et al., 2014). The prognosis
for patients who develop recurrent GBM is poor with a median survival  of 12-15
months (Stupp et al., 2009). Treatment options for recurrent GBM are limited and no
universally standard of care protocol is available so far (van Linde et al., 2017), thus,
representing a need for alternative treatment options.
A study conducted in the frame of The Cancer Genome Atlas (TCGA) classified four
molecular subtypes in GBM: classical, mesenchymal, proneural and neural subtypes
(Verhaak et al.,  2010). Recently,  the authors retracted the neural  subtype due to
possible  contamination  with  non-tumor  tissue  (Wang  et  al.,  2017).  The  three
remaining  subtypes  differ  in  clinical  prognosis  while  patients  with tumors  of  the
classical  and  mesenchymal  subtype  have  a  significantly  reduced  overall  survival,
which  was  not  observed  for  the  proneural  subtype  (Verhaak  et  al.,  2010).  The
characteristic alterations in the subgroups were mainly based on the expression of
EGFR (classical), NF1 (mesenchymal) and PDGFRA/IDH1 (proneural).
A.1.1 Biomarkers in GBM
Generally, biomarkers are defined as biological molecules detected in body fluids or
tissue that are a sign for a normal or abnormal process, of a condition or disease (NCI
Dictionary of Cancer Terms). Biomarkers can be diagnostic, prognostic or predictive,
while  prognostic  biomarkers  predict  the  outcome  of  a  disease  regardless  of  a
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treatment and predictive biomarkers are associated with the outcome of a specific
therapy. Biomarkers may also fit into more than one category, so that a biomarker
can be prognostic and predictive at the same time  (Kang et al., 2015). Biomarkers
require robust clinical performance in terms of high specificity and sensitivity and
prognostic value (Kang et al., 2015).
Currently, the strongest biomarker for outcome and benefit of TMZ chemotherapy in
GBM  is  methylation  of  the  O6-methylguanine-DNA  methyltransferase  (MGMT)
promoter  (Stupp et  al.,  2009).  TMZ is  a  DNA methylating agent  most  commonly
modifying  N7-methylguanine  and  N3-methyladenine  (Trivedi  et  al.,  2005).
Methylation events which yield O6-methylguanine are highly cytotoxic if the methyl
group is not removed before cell division (Liu et al., 2002). MGMT is a cellular DNA
repair  protein  that  reverses  methylation  at  the  O6 position  of  guanine,  thereby
neutralizing the effects of TMZ (Hegi et al., 2008). Thus, clinical outcome of patients
treated  with  alkylating  agents  such  as  TMZ  in  combination  with  radiotherapy  is
significantly improved in the presence of a MGMT promoter methylation. The 18-
month  survival  rate  of  patients  with  MGMT  promoter  methylation  was  62%
compared to a survival of 8% in the absence of the promoter methylation (Hegi et
al., 2004). 
Additionally  several  prognostic  biomarkers  have  been  identified  with  regard  to
overall  survival  of  GBM  patients:  these  include  age  at  diagnosis,  the  Karnofsky
performance  score,  resection  status  and  presence  of  particular  molecular
aberrations (Laws et al., 2003; Delgado-López and Corrales-García, 2016). Important
molecular genetic alterations are MGMT promoter methylation, 1p/19q co-deletion
and mutations in  IDH1/IDH2 (isocitrate dehydrogenase) gene. The  IDH1 enzyme is
part of the citric acid cycle and catalyzes the reaction of isocitrate to α-ketoglutarate
yielding nicotinamide adenine dinucleotide phosphate (NADPH).  IDH1 serves as a
major source for NADPH production in the cytoplasm.  IDH1 mutation is commonly
found in secondary GBM but rarely present in primary GBM  (Sanson et al., 2009).
1p/19q co-deletions are common in oligodendrogliomas and are correlating with a
significantly  higher  overall  survival  (median  survival  14.9  years  versus  4.7  years)
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(Fallon et al., 2004). 1p/19q co-deletions are rare in GBM (von Deimling et al., 2000)
but it could be shown that GBM patients with oligodentric tumor areas exhibit a
beneficial prognosis (He et al., 2001).
A.1.2 MicroRNA (miRNA) biogenesis and function
As described above,  the outcome of  GBM patients strongly  differs based on the
individual  biologic  background  and  prognosis.  Therefore,  for  individualized
treatment  of  the  patients  the  definition  of  subgroups  is  a  prerequisite.  For  this
purpose, miRNAs can be utilized for stratification of patient groups. MiRNAs are a
large family  of  small  non-coding  RNA that  regulate  mRNA expression  on  a  post-
transcriptional  level.  During  the  last  decade,  there  was  a  significant  gain  of
knowledge on the function and role of miRNAs. In mammals, miRNA are thought to
control the majority of all protein-coding genes (Friedman et al., 2009) and miRNAs
play a role in every cellular process investigated so far  (Bartel, 2009;  Carthew and
Sontheimer, 2009; Krol et al., 2010). The history of miRNAs started early 2000s with
only  a  handful  miRNAs  known  (Bartel,  2004) and  developed  to  currently  38589
entries listed in www.mirbase.org   (Griffiths-Jones, 2004). 
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Figure 1: Overview of miRNA biogenesis pathway
MicroRNA genes  are  transcribed  by  RNA polymerase  II  as  primary  miRNAs  (pri-
miRNAs).  The  long  pri-miRNAs  are  processed  by  DROSHA to  generate  precursor
miRNAs  (pre-miRNAs).  The  pre-miRNAs  are  transported  into  the  cytoplasm  by
exportin 5 (XPO5). Afterwards, the pre-miRNAs are loaded into the DICER complex to
form miRNA duplexes that are processed by Argonaute (AGO) proteins to create
mature miRNAs. The mature miRNAs are incorporated into a miRISC complex for
silencing of mRNA. (adapted from Lin and Gregory, 2015)
MiRNAs are transcribed by RNA polymerase II  (Figure 1) as primary miRNAs (pri-
miRNAs).  Those long transcripts  may inherit  multiple miRNA loci  and are further
processed in the nucleus by the DROSHA protein complex. The regulation of miRNA
expression is complex and the presence and the locations of most miRNA promoters
are  still  under  investigation.  Localization  of  the  promoters  was  performed  by
analyzing CpG Islands, RNA sequencing and Chromatin Immuno-precipitation DNA-
Sequencing (ChIP-seq) data  (Ozsolak et  al.,  2008).  Additionally,  some miRNAs are
encoded on introns of protein-coding genes and share the promoter of the host gene
(Ha and Kim, 2014). Furthermore, it has been speculated that intronic miRNAs may
also have promoters  distinct  from their  host  genes  (Monteys  et  al.,  2010).  After
5
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transcription, the pri-miRNAs undergo several steps of maturation. Generally,  pri-
miRNAs consist of multiple stem-loop structures in which the mature miRNAs are
located (Lee et al., 2002). The pri-miRNAs are processed by DROSHA that crops the
stem-loops and hairpin-like precursor miRNAs (pre-miRNAs) are formed (Ha and Kim,
2014).  Intronic  miRNAs  form  precursor  structures  independent  from  DROSHA.
Thereby, hairpin structures are created directly after splicing from host mRNA (Ruby
et al., 2007).
Further processing of the miRNAs is completed in the cytoplasm. Therefore, the pre-
miRNAs are transported into the cytoplasm by a transport protein complex XPO5
(Exportin 5) (Bohnsack et al., 2004). Afterwards, DICER cleaves the pre-miRNAs and
small RNA duplexes are formed  (Ketting et al.,  2001). For creation of the mature
miRNAs, the RNA duplexes are loaded into Argonaute (AGO) proteins. In humans,
multiple AGO proteins exist (Dueck et al., 2012) which unwind the double stranded
RNA  and  create  mature  single  stranded  miRNA.  In  combination  with  the  AGO
proteins, miRNAs form RNA-induced silencing complexes (RISC) that bind to mRNA
and induce silencing of the targets (Kawamata and Tomari, 2010). Generally, miRNA
target  inhibition  is  either  achieved  by  repression  of  translation  or  by  target
degradation (Huntzinger and Izaurralde, 2011).
In this study, the function of the human miRNAs, let-7a-5p, let-7b-5p, miR-125a-5p
and miR-615-5p was analyzed. The miRNAs let-7a and let-7b belong to the same
miRNA family (called lethal-7) that was one of the first discovered miRNAs. The let-7
miRNA  plays  an  important  role  in  the  developmental  timing  in  Caenorhabditis
elegans since  mutants  carrying  an  altered  let-7  miRNA  die  during  development
(Reinhart et al., 2000). The let-7 family consists of multiple miRNAs (distinguished by
letters) that all carry the same seed sequence. This highly preserved sequence spans
from nucleotide 2 through 8 and is an essential part for target recognition of the
RISC  complex  (Brennecke  et  al.,  2005).  Lower  developed  organisms  like
Caenorhabditis elegans or Drosophila melanogaster only have one let-7 miRNA while
higher developed animals have multiple let-7 family members. Usually, each let-7
family member is present in multiple copies across the genome. Let-7a has three
6
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different  precursor  sequences  let-7a-1  (human  chromosome  9),  let-7a-2  (human
chromosome  11)  and  let-7a-3  (human  chromosome  22).  All  of  these  precursors
encode the same mature miRNA let-7a-5p (Lee et al., 2016). Additionally, all of the
let-7a precursors are encoded on polycistronic miRNA clusters. Notably, let-7a-3 is
on a miRNA cluster on chromosome 22 that also contains the only copy of let-7b,
suggesting that the regulation of these miRNAs is linked. The let-7 miRNA family is
well-investigated and is believed to promote differentiation during development and
let-7 is supposed to be a tumor suppressor in various cancers (Lee et al., 2016).
The human miRNA family miR-125 consists of only three family members, miR-125a
(human  chromosome  19),  miR-125b-1  (human  chromosome  11)  and  miR-125b-2
(human chromosome 21). It has been reported, that the miR-125 family members
play  an  important  role  in  differentiation  of  cells,  proliferation  and  apoptosis
(Bousquet et al., 2012). Furthermore, miR-125 acts as tumor suppressor in various
cancers. In lung cancers, miR-125a suppresses cell migration and invasion. It could be
shown that the expression of miR-125a in lung tumor and lymph node metastasis
was much lower than in adjacent normal lung tissues  (Jiang et al.,  2010).  Similar
observations were made in ovarian cancer cells (Cowden Dahl et al., 2009). It could
be  shown,  that  the  oncogene epidermal  growth factor  receptor  (EGFR)  signaling
leads to translational repression of miR-125a. 
In contrary to the other miRNAs of the signature, much less is known about the
human miR-615. Unlike the other miRNAs, miR-615 is an intronic miRNA, located in a
homeobox gene  Hoxc5 (Quah and Holland, 2015).  Thus,  transcription of the host
gene also generates miR-615. Notably, it could be shown that miR-615 may also be
generated independently,  suggesting that the miRNA possesses its own promoter
(Quah and Holland, 2015). The role of intronic miRNAs is sparsely investigated, yet it
could be shown that intronic miRNAs perform complementary functions with its host
gene (Quah et al., 2015).
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A.1.3 A 4-miRNA signature predicts the clinical outcome in GBM
Only  few prognostic factors  have been identified in  GBM and novel  markers  for
stratifying patients into specific prognosis and treatment groups are needed. One
approach utilizes miRNAs for predicting the clinical survival of GBM patients. In an
own study we identified a 4-miRNA signature that predicts overall survival in GBM
and allows to the stratification into high- and low-risk GBM patients  Niyazi  et al.,
(2016).  The  risk  groups  can  be  considered  for  the  development  of  alternative
therapeutic  approaches  including  radiochemotherapy  escalation/de-escalation
strategies. We discovered the signature in GBM patients retrospectively collected at
the Frankfurt University clinics. Applying machine learning methodology on miRNA
microarray  profiles  of  resectates  or  biopsies  from these  patients  we identified a
prognostic model including the four miRNAs hsa-let-7a-5p, hsa-let-7b-5p, hsa-miR-
125a-5p and hsa-miR-615-5p. The model significantly predicted overall  survival  of
standard-of-care  treated  GBM patients  and was validated in  a  carefully  matched
(therapy, sex and age) matched subset of GBM patients of the TCGA GBM cohort.
The signature is independent of sex, age and MGMT promoter methylation status
and  we recently  were  able  to  validate  it  in  a  pooled  multicenter  cohort  of  106
patients (data unpublished). Furthermore, the median risk score of the patients was
calculated from the cumulative expression levels of the four miRNAs that assigns
individual  patients  to either  high-  or  low-risk  groups.  The median survival  of  the
patients  of  the high-risk  group was 13.5 months  and the survival  of  the low-risk
group  was  18.4  months.  The  signature  was  discovered  using  global  miRNA
expression  from 36  GBM patients.  A  forward  selection approach  was  utilized  to
unveil differentially expressed miRNAs. We discovered that high expression of let-7a-
5p, let-7b-5p and miR-125a-5p correlated positively with overall survival while the
expression of miR-615-5p correlated negatively with outcome. In combination with
the MGMT promoter methylation status, the subgroups could further be split into
four risk strata that further increased the prognostic accuracy in comparison to the
strata defined by MGMT promoter methylation or by the miRNA signature alone.
These  findings  proposed  further  investigation  of  the  biologic  function  of  the
8
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signature miRNAs. Little is known about the functional role of the four miRNAs in
GBM. This demands for further investigation of the biologic role of the miRNAs and
the potential mRNA targets. In this thesis, the 4-miRNA signature was validated and
a  translational  approach  was  followed to  characterize  the  4-miRNA signature  as
described below.
A.1.4 Genome editing using site specific nucleases
For the analysis of the functional impact of miRNAs in model systems, one approach
is  to  modulate  the  expression  of  the  miRNAs  by  stable  knockouts  or  transient
transfections.  Transient modulation of  miRNA expression is usually performed by
transfection of small RNA molecules that either mimic the miRNA function or reduce
the amount of available miRNAs in the cell. Like natural miRNAs, mimics are double
stranded RNAs that inherit an active forward strand, which can be incorporated in
the AGO complex. The reverse strand is non-functional and gets degraded in this
process.  Anti-miRNA  oligonucleotides  are  reverse-complementary  to  the  target
miRNAs  which bind to  the miRNA and thereby block  their  function  (Lennox  and
Behlke, 2011). In this study, we investigated the use of CRISPR (clustered regularly
interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein) system for
stable knockout of the miRNAs. 
CRISPR is originating from bacteria (Jansen et al., 2002) and represent an important
tool  for  simple  and  efficient  genome  editing  (Wang  et  al.,  2016).  Unlike  other
sequence  specific  genome  editing  tools  like  zinc  finger  nucleases  (ZNFs)  or
transcriptor activator-like nucleases (TALENs) (Figure 2), CRISPR mediated genome
editing  does  not  need  specifically  engineered  proteins  for  target  recognition.
Generation of genetic mutations by CRISPR requires a 20-nuclease long guide RNA
that utilizes base pairing to recognize and bind to the target site. The Cas9 nuclease
interacts with a short protospacer-adjacent motif (PAM) directly next to the guide
sequence (Jinek et al., 2012; Gasiunas et al., 2012; Garneau et al., 2010; Marraffini
and Sontheimer, 2008;  Bolotin et al.,  2005). Cas9 can be used to target any DNA
sequence by simply changing the guide RNA sequence, making it a versatile tool for
genome  editing.  The  mechanism  of  genome  editing  occurs  in  a  multiple-step
9
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process: Cas9 introduces double strand breaks (Jinek et al., 2012) that are repaired
by the cell  afterwards.  Two different  repair  pathways  exist,  nonhomologous  end
joining (NHEJ) and homology-directed repair (HDR).
Figure 2: Overview of sequence-specific tools for genome editing
Comparison  of  programmable  sequence-specific  genome  editing  nucleases.  Zinc-
finger nucleases (ZFNs) and transcriptional activator-like effector nucleases (TALENs)
utilize DNA-binding domains fused to FokI nucleases to recognize and cut DNA. Cas9
is a RNA-guided nuclease that recognizes its target DNA using 20 nucleotide guide
RNAs that interact with the DNA. (adapted from Wang et al., 2016)
10
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NHEJ introduces random deletions and insertions at the DNA double-strand break
that may cause frame-shifts in protein coding sequences or alter critical regions in
regulatory elements (Lieber, 2010). Double-strand breaks can also be utilized by HDR
to introduce donor DNA at the CRISPR target site. Therefore, constructs harboring
homologous regions flanking the upstream and downstream regions, are designed to
insert  novel  DNA  sequences  at  the  break  (Choulika  et  al.,  1995).  Various  gene
modifications  can  be  introduced  by  HDR:  targeted  gene  deletion,  mutation  or
insertion (Wang et al., 2016). 
Mutations caused by the CRISPR/Cas9 technology generally require transfection of
multiple plasmids followed by screening and selection of mutants and are quite time
intensive. Less time consuming knockdown (and overexpression) of miRNAs can also
be achieved by transfection of small interfering RNA (siRNA) that either inhibit (or
mimic) miRNA function  (Lam et al., 2015). A major disadvantage of this method is
the short-term effect by the transfected siRNAs that usually lasts 5-7 days. These
synthetic miRNAs (also known as miRNA mimics) are short RNA duplexes that can be
used to target and silence mRNA. Similar to miRNAs, synthetic mimics are processed
in the DICER complex that trims the double stranded RNA. Afterwards, the mimics
are  incorporated  in  the  RISC/AGO  protein  complex  that  allows  inhibition  of  the
target mRNA (Agrawal et al., 2003, Lam et al., 2015). Furthermore, miRNA function
can be suppressed by transfection of synthetic miRNA inhibitors. These molecules
consist of single-stranded RNA that resemble the reverse complement of the mature
miRNA  (Robertson  et  al.,  2010).  Additionally,  miRNA  inhibitors  are  chemically
modified in order to prevent RISC-induced cleavage of the inhibitor/miRNA duplex.
The  modifications  also  grant  enhanced  binding  affinity  and  make  the  inhibitors
resistant to nucleolytic degradation (Esau, 2008). 
A.2 Aims
The overall aims of my study were the validation of the four signature miRNAs and
the elucidation of the molecular impact of these miRNAs in GBM in vitro models. As
for this purpose, the secondary aim was the identification of suitable in vitro tumor
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model systems. Thus, a panel of seven established GBM cell lines was characterized
with respect to cytogenetic, transcriptomic and DNA methylation properties.  
The first step was to authenticate the cell lines using STR-typing in combination with
cytogenetic analysis by spectral karyotyping in order to characterize chromosomal
aberrations,  ploidy  and  clonality  of  cell  lines.  A  further  aim was  to  validate  the
signature in the analyzed cell line panel and in GBM patient samples using qRT-PCR.
Moreover, the cell lines were analyzed for resistance towards ionizing radiation and
TMZ. Additionally, I analyzed the expression of the GBM risk signature miRNAs and
associations between phenotypic properties and miRNA expression. Moreover, the
global  gene  expression  profiles  of  the  cell  lines  were  generated  and  analyzed
including molecular subtyping. These data were supposed the basis for the selection
of cell lines to be used in miRNA modulation experiments.
In the selected cell culture models the expression of the 4-miRNAs was modified by
CRISPR  knockout  and  transient  transfection  of  miRNA  mimics  and  inhibitors.  A
specific aim was to introduce a CRISPR/Cas9 knockout system in specific cell lines in
order to modify the miRNA expression in selected cell  lines.  Another aim was to
observe changes in the transcriptome prior and post transfection with miRNA mimics
and inhibitors. Changes in the expression profiles between treated and untreated
cell lines should be characterized by RNA sequencing. Differences in gene expression
profiles were thought  to provide insights into the molecular networks of the risk
signature miRNAs and to unveil their functional role in the context of glioblastoma.
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B Material and methods
B.1 Materials
B.1.1 Cell lines
Table 1 Cell lines used in this study
Cell line Origin Supplier
A172
LN18
LN229
T98G
U87-MG
U138-MG
U251-MG
Male, grade IV 
glioblastoma
Male, grade IV 
glioblastoma
Female, grade IV 
glioblastoma
Male, grade IV 
glioblastoma
Male, origin unknown, 
possibly glioblastoma
Male, grade IV 
glioblastoma
Male, grade IV 
glioblastoma
American type culture 
collection (ATCC, 
Manassas, VA, USA)
ATCC
ATCC
ATCC
ATCC
Cell line service (CLS 
GmbH, Eppelheim, 
Germany)
CLS
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B.1.2 Solutions
Table 2 Buffers and solutions
Solution Reagent Concentration
20x SSC buffer NaCl2 (Sigma-Aldrich)
Trisodium citrate (Sigma-Aldrich)
HCl (Merck)
3 M
300 mM
ad 1 M ad to pH 7.0
5x ISO buffer Tris-HCl pH 7.5 (Sigma-Aldrich)
MgCl2 (Sigma-Aldrich)
dGTP (New England Biolabs)
dCTP (New England Biolabs)
dATP (New England Biolabs)
dTTP (New England Biolabs)
DTT (Sigmal-Aldrich)
PEG-8000 (Sigmal-Aldrich)
NAD (New England Biolabs)
dH2O
1 M
2 M
100 mM
100 mM
100 mM
100 mM
1 M
1.5 µg
100 mM
ad to 6 ml
Agarose gel Agose (Serva)
TE buffer 
0.5 to 1 g (1 or 2%)
ad to 500 ml
Cresol red Ficoll 400 (Fluka)
dH2O
10 g
ad 100 ml
DAPI / Vectashield 
solution
4',6-diamidino-2-phenylindole
(DAPI) (Sigma-Aldrich)
Vectashield (Vector)
0.1%
ad to 1000 µl
Denaturation solution Formamide deionized 
(Applichem)
SSC (Sigma-Aldrich)
dH2O
HCl (Merck)
70%
2x
ad to 100 ml
ad 1 M to pH 7.0
Fixation  solution  for
cell staining
Ethanol (Merck)
Methylene blue (Sigma-Aldrich)
80%
0.3%
Fixation solution for 
metaphase prep.
Glacial acetic acid (Merck)
Methanol (Merck)
25%
75%
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Solution Reagent Concentration
Gibson assembly 
master mix
ISO Buffer
T5 exonuclease (New England 
Biolabs)
Phusion polymerase (New 
England Biolabs)
Taq polymerase (New England 
Biolabs)
dH2O
5x
6.4 U
40 U
6400 U
ad to 1.2 ml
MgCl2 / PBS PBS 
MgCl2 (Sigma-Aldrich)
dH2O
1x
50 mM
ad to 200 ml
Pepsin solution Pepsin (Sigma-Aldrich)
HCl (Merck)
dH2O
0.001%
10 mM
ad to 100 ml
Phosphate buffered 
saline (PBS)
PBS  Dulbecco  without  Ca2+ and
Mg2+ (Biochrom)
dH2O
9.55 g / l 
ad to 10 l
Post fixation solution Formaldehyde (Honeywell)
MgCl2 / PBS
1%
ad to 74 ml
SSC / Tween wash 
solution
SSC (Sigma-Aldrich)
Tween 20 (Sigma-Aldrich)
4x
0.1%
STE buffer NaCl (Sigma-Aldrich)
Tris-Cl pH 8.0 (Sigma-Aldrich)
EDTA (Sigma-Aldrich)
100 mM
10 mM
1 mM
Temozolomide (TMZ) Temozolomide (Tocris)
Dimethlysulfoxide (Sigma-Aldrich)
10 mg
ad 1.03 ml
Tris-EDTA (TE) buffer Tris (Merck)
EDTA (Merck)
dH2O
HCl (Merck)
10 mM
1 mM
ad 1000 ml
ad 1 M to pH 7.5
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B.1.3 Primers used in this study
Table 3 Sequence information of primers used in this study
Primer name Sequence Description
OS280 CAGGGTTATTGTCTCATGAGCGG sequencing primer for MLM3636 fwd
Fwd let-7a TTGTGGAAAGGACGAAACACTTTAGGGTCACACCCACCACTTTTAGAGCTAGAAATAGCAAGTT gibson fwd primer for single guide cloning of let-7a in MLM3636
Rev let-7a TGCTATTTCTAGCTCTAAAAGTGGTGGGTGTGACCCTAAAGTGTTTCGTCCTTTCCACAAGATA gibson rev primer for single guide cloning of let-7a in MLM3636
Fwd let-7b TTGTGGAAAGGACGAAACACGGTTGTATAGTTATCTTCCGTTTTAGAGCTAGAAATAGCAAGTT gibson fwd primer for single guide cloning of let-7b in MLM3636
Rev let-7b TGCTATTTCTAGCTCTAAAACGGAAGATAACTATACAACCGTGTTTCGTCCTTTCCACAAGATA gibson rev primer for single guide cloning of let-7b in MLM3636
Fwd miR-125a TTGTGGAAAGGACGAAACACTGGATGTCCTCACAGGTTAATTTTAGAGCTAGAAATAGCAAGTT gibson fwd primer for single guide cloning of miR-125a in MLM3636
Rev miR-125a TGCTATTTCTAGCTCTAAAATTAACCTGTGAGGACATCCAGTGTTTCGTCCTTTCCACAAGATA gibson rev primer for single guide cloning of miR-125a in MLM3636
MLM3636-rev-seq CAAGCTGGGCTGTGTGC sequencing primer for MLM3636 rev
5’-arm-fwd-let7a GGTACGGGCCCATCGATAAGCTTGCATGTGGCTATACAGCCGTCAG gibson fwd primer for amplification of the 5' region of let-7a into pFG4
3’-arm-fwd-let7a ATGCTATACGAACGGTACATCCGGATCCGTGATAGAAAAGTCTGCATCCAGGCG gibson fwd primer for amplification of the 3' region of let-7a into pFG4
3’-arm-rev-let-7a CACCGCGGTGGCGGCCGCTCTAGAGCACTGTGTGAATGAAGGACTACTTCAGG gibson rev primer for amplification of the 3' region of let-7a into pFG4
5’-arm-fwd-let7b GGTACGGGCCCATCGATAAGCTTGCAGGAGGTGCCTCTGGAAG gibson fwd primer for amplification of the 5' region of let-7b into pFG4
3’-arm-fwd-let7b ATGCTATACGAACGGTACATCCGGATCCTGAGGAGCCCAGTGACAC gibson fwd primer for amplification of the 3' region of let-7b into pFG4
3’-arm-rev-let-7b CACCGCGGTGGCGGCCGCTCTAGAGAGGACTGGCACAGATGGGTGTC gibson rev primer for amplification of the 3' region of let-7b into pFG4
5’-arm-fwd-
miR125 
GGTACGGGCCCATCGATAAGCTTGCTGAGTCCTTGGATTCCAGG gibson fwd primer for amplification of the 5' region of miR-125a into pFG4
3’-arm-fwd-
miR125 
ATGCTATACGAACGGTACATCCGGATCCCACAGGTGAGGTTCTTGGGAG gibson fwd primer for amplification of the 3' region of miR-125a into pFG4
3’-arm-rev-miR125 CACCGCGGTGGCGGCCGCTCTAGAGATGCTTCCTGAGTCCCTCCCAAG gibson rev primer for amplification of the 3' region of miR-125a into pFG4
7a-fwd-2 TAGGAACTGTAAGAAAACCAGCAG Forward primer for T7 assay let-7a
7a-rev-2 CAAGTCTACTCCTCAGGGAAGGCA Reverse primer for T7 assay let-7a
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Primer name Sequence Description
7b-fwd-2 CTGAGCCGTACCCTCCACTGAGCA Forward primer for T7 assay let-7b
7b-rev2 TTGGCAGTGCTCTGAGCTGCTGAC Reverse primer for T7 assay let-7b
125a-fwd-1 CTGTCTGTCTGTCTGTCGGGTC Forward primer for T7 assay miR-125a
125a-rev-1 CTGACTGTTTCTCTCTGTCTGTCCCTC Reverse primer for T7 assay miR-125a
miRNA-rev GAATCGAGCACCAGTTACG Universal reverse primer for SYBR green qRT-PCR
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B.2 Cell culture
B.2.1 Cultivation of cell lines
Material
 Cell culture flasks (Greiner) 175 cm2
 Countess cell counter (Thermo Fisher)
 Counting chamber Countess (Thermo Fisher)
 Cryo preservation chamber (Nalgene)
 Cryotubes 1.0 ml (Nunc)
 Culture medium DMEM Glutamax (Thermo Fisher), supplemented with 10%
fetal  calf  serum  (FCS)  (Sigma-Aldrich)  and  1%  Penicillin/Streptomycin
(Thermo Fisher)
 Falcon tubes (Falcon) 50 ml
 Freeze  medium  (Culture  medium  supplemented  with  10%  DMSO  (Sigma-
Aldrich))
 Incubator 37°C, 7.5% CO2 (Sigma)
 Microscope (Olympus)
 PBS
 Plastic pipettes (Greiner)
 Dissociation solution TrypLE Express (Thermo Fisher) 
Procedure
All GBM cell lines were cultivated in a cell culture incubator at 37°C and 7.5% CO2. 
The cells were passaged twice per week at a confluency of approx. 80%. All work was
performed under sterile environment in a laminar flow bench. 
Subculturing
After removal of the cell culture medium, the cell culture flask was washed with 10 
ml PBS. The adherent cells were detached from culture vessel using 4 ml TrypLE 
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Express followed by incubation at 37°C for five minutes. Complete detachment was 
confirmed using a microscope. The reaction was stopped adding 6 ml culture 
medium and the suspension was transferred to a 50 ml falcon tube. The cells were 
centrifuged for five minutes at 300 g and the supernatant was discarded. The pellet 
was resuspended in cell culture medium and 10 µl was taken for cell counting. The 
cells were seeded in amounts of 5x105 to 1x106, depending on the cell line and 
subculturing duration, in 20 ml medium in a 175 cm2 cell culture flask.
Cryo-preservation of cells
For long-term preservation, the cells are stored in cryotubes (1x106 cells per tube) in 
liquid nitrogen. After centrifugation for 5 min at 300 g, the supernatant was 
discarded and the cells were resuspended in freeze medium (culture medium 
supplemented with 10% DMSO). Before the vial was stored in liquid nitrogen, it was 
put in a cryo-preservation chamber and placed on -80°C for 24 hours.
B.2.2 GBM cell line panel
The human GBM cell lines A172, LN18, LN229, T98G, U87-MG, U138-MG and U251-
MG (Table 1) were analyzed in this study. A172, LN18, LN229, U87-MG and T98G
were obtained from the American type culture collection (ATCC, Manassas, Virginia,
USA), U138-MG and U251-MG from a German cell lines repository (CLS, Eppelheim,
Germany). As described in B.1.3, all cell lines were authenticated by STR typing.
B.2.3 STR Typing
Short tandem repeat (STR) analysis was utilized to characterize the origin of the cell
lines used for this study. STRs contain two to thirteen base pair sequences that are
repeated  hundreds  of  times  on  a  specific  position  on  the  DNA.  The  STRs  were
amplified using PCR and the size of the resulting products was characterized. The
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resulting STR profiles were compared to validate profiles from the DSMZ database
(www.dsmz.de).
Material
 96-well PCR plates (Thermo Fisher)
 96-well Barcode plates (Thermo Fisher)
 Applied biosystems genetic analyzer (Thermo Fisher)
 DSMZ database (Reinhart et al., 2000)
 GeneAmp PCR System 9700 (Applied Biosystems)
 Genemapper software (Thermo Fisher)
 Geneprint 10 system (Promega)
5X Master Mix
5X Primer Pair Mix
Amplification grade water
2800M Control DNA, 10 ng/µl
Allelic Ladder Mix
Internal Lane Standard 600
 Hi-Di formamide (Thermo Fisher)
Procedure
For  cell  line  authentication,  STR-typing  was  performed  using  the  Geneprint  10
system.  For  setting  up  the  PCR  amplification  of  the  short  tandem  repeats,  5  µl
Master Mix and 5 µl Primer Pair Mix was added to 10 ng genomic DNA which was
extracted as described in B.1.4. For the positive control, 2800M Control DNA was
used. The samples were vortexed and transferred to 96-well  PCR plates. Thermal
cycling  was  carried  out  in  a  GeneAmp  PCR  System  9700  using  the  following
conditions:
96°C for 1 min
94°C for 10 sec
59°C for 1 min
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72°C for 30 sec 
These steps were repeated for 30 cycles
60°C for 10 min
4°C ∞
Afterwards, the PCR products were diluted 1:10 and 1:50. A loading cocktail  was
prepared using 9.5 µl Hi-Di formamide and 0.5 µl Internal Lane Standard 600. The
mix was vortexed and transferred to 96-well Barcode plates. 1 µl of the diluted DNAs
were added to the loading cocktail. The samples were denatured at 95°C for 3 min
and immediately chilled on ice. Evaluation of the STR-markers was carried out using
an Applied Biosystems genetic analyzer and analysis of the data was performed using
the Genemapper software. The size standard ‘ILS600’ and the Promega Geneprint 10
analysis  panel  were  utilized  in  the  software.  The  determined  genotypes  were
compared to the DSMZ database (www.dsmz.de).
B.2.4 Spectral karyotyping
Material
 15 ml centrifuge tubes (Falcon)
 Antidigoxigenin antibody (Roche)
 Avidin-Cy-5 antibody (Biomol)
 Avidin-Cy-5.5 antibody (Biomol)
 Colcemid (Roche)
 Coplin jar
 Fixogum
 Fluorescence microscope ZEISS Axioplan 2 (ZEISS)
 Heat block
 Metal box for incubation
 Microscope slides
 SKY-probe mixture SkyPaint DNA Kit (Applied Spectral Imaging)
 SpectreCube device and SkyView software (Applied Spectral Imaging)
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 Water bath
Solutions (Table 2)
 DAPI / Vectashield solution
 ddH2O
 Denaturation solution
 Dissociation solution TrypLE express (Thermo Fisher)
 Ethanol 70%, 90%, 100% (Merck)
 Fixation solution
 KCl 0.4%, 4%
 MgCl2 / PBS 
 PBS
 Pepsin solution
 Post fixation solution
 RNase 10 mg / ml (Fermentas)
 SSC 2x
 SSC/Tween wash solution
Procedure
For karyotyping, the cells were cultivated to 80% confluency as described in B.2.1.
Chromosome spreads were prepared by addition of  colcemid to the cell  culture
medium for 3 hours at 37°C. Afterwards, the medium was removed and the cells
were  washed  with  PBS  and  detached  from  the  cell  culture  flask  using  TrypLE
Express.  The  cell  solution  was  transferred  into  15  ml  centrifuge  tubes  and  the
samples  were  centrifuged  for  8  min,  1000  rpm  at  room  temperature.  The
supernatant was discarded and 750 µl 0.4% KCl was added drop wise to the cell
pellet. Afterwards, 4% KCl was added to a total volume of 10 ml. The samples were
incubated for up to 45min at 37°C. Afterwards, 600 µl fixation solution was added to
the mix. The tubes were centrifuged for 5min, 1000 rpm at room temperature and
the  supernatant  was  discarded.  The  pellet  was  resuspended  in  10  ml  fixation
solution and incubated for 45min at 4°C. Afterwards, the cells were centrifuged for 5
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min,  1000  rpm  at  room  temperature  and  the  pellet  was  washed  with  fixation
solution.  The  wash  procedure  was  repeated  two  times  and  the  cells  were
resuspended in  up  to  2  ml  fixation  solution.  The  suspension  was  dropped onto
microscope slides and was kept at room temperature.
For  hybridization,  the  following  steps  were  performed  in  coplin  jars  at  room
temperature unless specified. Initially, the samples were washed in 2x SSC for 3min
and the slides were treated in a metal box with RNase for 4 min at 37°C. Afterwards,
the slides were washed three times in 2x SSC for 2 min. The samples were treated
using pepsin solution for 2min at 37°C in a water bath. Afterwards, the slides were
washed in PBS for 5 min followed by an MgCl2 / PBS wash for another 5 min. The
samples were briefly washed with PBS and incubated in post fixation solution for 10
min. After another brief wash with PBS, the samples were incubated in PBS for 5 min
and in 2x SSC for 2 min. The samples were treated in denaturation solution for 5 min
at 72°C in a water bath and the reaction was stopped using 70% ethanol for 2 min at
-20°C followed by incubation for 2 min in 90% ethanol at -4°C and 2 min in 100%
ethanol at 4°C. The slides were allowed to dry on a heater for 5 min and the SKY-
probe was pipetted on the samples. Hybridization was carried out for 16 hours at
37°C in a water bath. After hybridization, slides were washed using 0.5 × SSC 5 min
at  75°C in  a  water bath followed by 4  ×  SSC/0.1% Tween 20 for  2 min at  room
temperature and H2O 2 min at room temperature. The probes were detected using
antidigoxigenin (1 : 250 dilution), avidin-Cy-5, and avidin-Cy-5.5 antibodies (both 1 : 
100  dilution)  according  to  the  manufacturers  protocols.  Afterwards,  metaphase
spreads  were  counterstained  using  DAPI  /  Vectashield  solution.  Acquisition  of
stained  metaphases  was  carried  out  using  a  fluorescence  microscope  (ZEISS
Axioplan  2)  equipped  with  SpectreCube  device  and  SkyView  software.  Each
individual  chromosome was determined by a combination of up to five different
fluorescent dyes (Table 4). Chromosomal aberrations could be identified by color
junctions on the altered chromosomes.
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Table 4: Combination of fluorescent dyes for SKY karyotyping
Chromosome Fluorescent dyes
1 BCD
2 E
3 ACDE
4 CD
5 ABDE
6 BCDE
7 BC
8 D
9 ADE
10 CE
11 ACD
12 BE
13 AD
14 B
15 ABC
16 BD
17 C
18 ABD
19 AC
20 A
21 DE
22 DBCE
X AE
Y CDE
A spectrum orange, B Texas red, C Cy5, D spectrum green, E Cy5.5. Modified after
Sanson et al., 2009
B.2.5 Microarray-based comparative genomic hybridization (aCGH)
Array CGH (aCGH) is a molecular cytogenetic method for determination of copy 
number variations compared to a reference sample. For this, an array is used which 
contains approx. 60.000 oligonucleotides that span the whole genome in approx. 13 
kb intervals. In the procedure, tumor and control DNA are labeled with fluorescent 
dyes. Afterwards, the samples are added to the array and the DNA hybridizes to the 
oligonucleotides on the array. The hybridized arrays are analyzed in a microarray 
scanner and the recorded signals are evaluated using bioinformatics tools.
24
Material and methods
B.2.5.1 Random prime labeling
Material
 Enzo CGH Labeling Kit for Oligo Arrays 
Primers/Reaction buffer
Cyanine 3-dUTP nucleotide mix
Cyanine 5-dUTP nucleotide mix
Klenow DNA-polymerase
Stop buffer
 Promega Human reference DNA (female or male) pooled 
 TE-buffer
Procedure
For random prime labeling 500 ng reference DNA was combined with 500 ng sample 
DNA. Therefore, the input DNAs were separately added to 20 µl Primer/Reaction 
buffer and 39 µl H2O. Afterwards, the samples were denatured at 99°C for 10 
minutes and chilled on ice for 2 minutes. To the tumor samples 10 µl Cy3-dUTP was 
added while 10 µl Cy5-dUTP was added to the reference samples. To each tube 1 µl 
Klenow-polymerase was added and the samples were incubated at 37°C for 4 hours. 
Afterwards, the reaction was stopped using 5 µl Stop-buffer. For purification of the 
DNA the samples were mixed with 430 µl TE-buffer and transferred to an Amicon 
Ultra-0.5-Filter. After centrifugation at 14000 g for 10 minutes, the flow-through was
discarded and the filter was inverted in a new reaction tube and centrifuged again at 
1000 g for 1 minute. Afterwards, the quality of the samples was evaluated using a 
Nanodrop ND-1000 device. For further processing of the samples, the specific 
activity (pmol fluorochrome per µg DNA) of the labeled DNA had to be at least 20 for
Cy5-labeled DNA and 25 Cy3-labeled DNA.
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B.2.5.2 Hybridization
Material
 Agilent 10x blocking agent
 Agilent 2x Hi-RPM buffer
 Agilent SurePrint G3 human CGH microarray, 4x180k
 Roche Human Cot-1 DNA 
Procedure
For hybridization, the volume of all samples hat to be 19,5 µl. Therefore, the samples
were dried in a vacuum rotator and the pellets were resuspended in 19,5 µl H2O. 
Afterwards, the reference and sample DNAs were combined. A hybridization master 
mix was created for one slide (four samples) using 21,25 µl Cot-1 DNA, 46,75 µl 
Agilent 10x blocking reagent and 233,75 µl Agilent 2x Hi-RPM buffer. To each 
sample, 71 µl of the master mix was added. The samples were denatured at 95°C for 
3 minutes and incubated at 37°C for 30 minutes. Afterwards, 100 µl of the sample 
was added to a chamber in a gasket slide. The array was placed on top of the gasket 
slide (with the Agilent label facing down) and the slides were sealed using a metal 
clamp. The array “sandwich” was placed in a rotating incubation oven at 65°C for 24 
hours. 
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B.2.5.3 Wash and scan of the arrays
Material
 Agilent Oligo aCGH/ChIP-on-chip wash buffer 1
 Agilent Oligo aCGH/ChIP-on-chip wash buffer 2
Procedure
Washing of the hybridized slides was carried out using two buffers, wash buffer 1 
which was kept at room temperature and wash buffer 2 which was preheated at 
37°C. The array “sandwiches” were carefully opened while submerged in wash buffer
1 and the gasket slide was allowed to detach from the hybridized array. Afterwards, 
the array was transferred to another cuvette containing wash buffer 1 and the slide 
was incubated for 5 minutes. The array was transferred into the cuvette containing 
wash buffer 2 at 37°C and incubated for 1 minute. For scanning of the array, the slide
was placed in an Agilent slide holder and covered using an ozone barrier. In the 
Agilent software, the profile “Agilent G3_CGH” was used for scanning of the slide. 
Afterwards, the resulting picture of the scanned slide was analyzed for uniform 
hybridization.
B.2.6 DNA-isolation from cell pellets
Material
 Ethanol 100% (Merck)
 PBS
 Qiagen Blood & Tissue Kit
DNeasy Mini Spin Columns
Collection tubes
Lysis buffer AL 
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Wash buffer AW1
Wash buffer AW2
Elusion buffer AE
Proteinase K
Procedure
For  DNA  isolation,  the  cell  lines  were  harvested  and  approx.  1x106 cells  were
centrifuged at 300 g for 5 min. Afterwards, the supernatant was discarded and the
pellet was resuspended in 200 µl PBS. After addition of 20 µl Proteinase K, 200 µl
Buffer AL was pipetted to the samples. The mixture was vortexed thoroughly. After
incubation at 56°C for 10 minutes, 200 µl ethanol was added and the samples were
transferred to spin columns. Afterwards, the columns were centrifuged at 6000g for
1 minute and the flow-through and collection tube was discarded. 500 µl Buffer AW1
was added to the column. The samples were centrifuged at 6000 g for 1 minute and
the flow-through was discarded. Afterwards, 500 µl Buffer AW2 was added and the
columns were centrifuged at 20,000 g for 3 minutes. The columns were transferred
to a microcentrifuge tube and 100 µl Buffer AE pipetted on the membrane. The DNA
concentrations were measured as described in B.2.1.
B.2.7 RNA-isolation from cell pellets
Material
 Chloroform (Merck)
 Ethanol (Merck)
 Qiagen miRNeasy Mini Kit
RNeasy Mini Spin Columns
QIAzol Lysis Reagent
Wash buffer RWT
Wash buffer RPE
RNase-Free water
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Procedure
The cells were harvested as described in 1.3 and 700 µl QIAzol Lysis Reagent was
pipetted onto the pellet. After 1 min of homogenization by vortexing, the mixture
was incubated for 5 min at room temperature. 140 µl Chloroform was added to the
samples and the contents were thoroughly mixed. The samples were incubated for 2
min at room temperature and centrifuged at 12000g for 15 min at 4°C. The upper
aquatic phase (approx. 350 µl) was transferred to a new tube and 525 µl ethanol was
added. The samples were pipetted into Spin columns and the tubes were centrifuged
at 8000g for 30 sec. The flow through was discarded and 700 µl Buffer RWT was
added onto the columns. The tubes were centrifuged at 8000 g for 30 sec and the
flow through was discarded. The columns were washed twice with 500 µl Buffer RPE
and were centrifuged at 8000 g for 30 sec and 2 min. Afterwards, the columns were
centrifuged another time at 8000 g for 1 min to remove residual buffer from the
columns. To elute the RNA, the columns were transferred into new collection tubes
and 30 µl water was pipetted onto the membranes. The samples were incubated for
1 min at room temperature and centrifuged at 8000 g for 30 sec. The resulting RNA
concentration was measured as described in B.2.1.
B.2.8 RNA-isolation in multi-well format
Material
 Ethanol 100% (Merck)
 PBS
 ZR-96 Quick-RNA Kit (Zymo)
RNA Lysis Buffer
RNA Prep Buffer
RNA Wash Buffer
DNase/RNase-Free Water
DNase I
DNA Digestion Buffer
Silicon-A Plate
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Collection Plate
Procedure
To analyze RNA from cells grown over a different period of time, culture dishes were
prepared to harvest the cells after 24, 48 and 72 hours.  At each time point,  the
culture medium was discarded, the cell  layer was washed once with PBS and the
cells were harvested. Afterwards, 100 µl lysis buffer was applied directly onto the
cells.  Cells  were  lysed  and  homogenized  by  pipetting  and  the  lysates  were
transferred into  a 96-well  plate  and stored in  -80°C until  further  processing.  For
isolation of the RNA, the samples were mixed with 100% ethanol in equal amounts
and transferred to a 96 well Silicon-A plate. The plates were centrifuged for 5min at
2500 g and the flow-through was discarded. Removal of residual DNA was carried
out by DNase I treatment directly onto the columns. Therefore, the samples were
washed with 400 µl RNA wash buffer once and the plates were centrifuged for 5min
at 2500 g and the flow-through was discarded. For each sample, 5 µl DNase I was
added  to  35  µl  DNA  digestion  buffer.  The  mix  was  added  to  the  columns  and
incubated at room temperature for 15 min and the plates were centrifuged for 5min
at 2500 g and the flow-through was discarded. Afterwards, 400 µl RNA prep buffer
was pipetted to the samples and the plates were centrifuged another time for 5min
at 2500 g. 500 µl RNA wash buffer was applied to the columns and the plates were
centrifuged for 5 min at 2500 g. This step was repeated once. For removal of residual
ethanol, the plates were centrifuged another time for 5min at 2500 g. The Silicon-A
plate was placed on top of an elution plate and 25 µl DNase/RNase free water was
added to the columns. The samples were centrifuged for 5min at 2500 g and the
resulting RNA concentrations were measured as described in B.2.1.
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B.2.9 Generation of cell lines with modulated signature miRNA 
expressions 
Lipofection-based transfection systems were used in  this  study  for  generation of
transgenic  cell  lines.  Lipofection  utilizes  positively  charged  liposomes  that  form
complexes  with  negatively  charged  DNA.  These  complexes  inherit  phospholipid
bilayers, which can easily merge with the cell membrane and deliver the DNA to the
cytoplasm of the cells. For these experiments the cell lines A172 and U138-MG were
used.
B.2.9.1 Determination of transfection efficiency and optimal 
concentration using siRNA
Material
 24-well cell culture plates (Greiner)
 Fluorescence-activated cell sorter (FACS) BD LSR II (BD Biosciences)
 Block-iT Alexa Fluor Red Fluorescent Control (Thermo Fisher), 20 µM stock
 Culture medium DMEM Glutamax (Thermo Fisher), supplemented with 10%
FCS (Sigma-Aldrich) and 1% Penicillin/Streptomycin (Thermo Fisher)
 DMEM Glutamax (Thermo Fisher) without additives
 Lipofectamine RNAiMAX transfection Reagent (Thermo Fisher)
 miRVana miRNA Inhibitor Negative Control #2 (Thermo Fisher), 20 µM stock
 mirVana miRNA Mimic Negative Control #1 (Thermo Fisher), 20 µM stock
 PBS
 Dissociation solution TrypLE Express (Thermo Fisher) 
Procedure
The  cells  were  seeded  in  24-well  plates  24  hours  prior  transfection.  The  stock
solutions  were  diluted  to  a  final  concentration  of  5  µM.  For  transfection,  two
microcentrifuge  tubes  were  prepared  as  described  below  and  the  respective
volumes were scaled according to the number of transfected wells. 25 µl additive-
31
Material and methods
free DMEM Glutamax was mixed with 1 µl of the respective siRNAs in the first tube,
resulting in a final concentration of 10 nM (alternatively 0.5 µl for a concentration of
5  nM).  In  the  second  tube,  25  µl  additive-free  DMEM  was  mixed  with  1.5  µl
RNAiMAX  reagent.  The  siRNA  mixture  of  tube  1  was  pipetted  into  the  tube
containing the RNAiMAX reagent. After 5 min incubation at room temperature, 50 µl
of the transfection mixture was added to the wells. Four hours after transfection, the
medium was replaced with fresh culture medium. The transfection efficiency was
determined 24-hours after transfection using FACS. Therefore, the culture medium
was  removed  from  the  wells  and  the  cells  were  washed  with  PBS  once.  For
detachment of the cells, 100 µl TrypLE Express was added to the wells and the plates
were incubated for 5 min at 37°C. Afterwards, 100 µl culture medium was pipetted
to the wells  and the suspension was transferred into microcentrifuge tubes.  The
tubes were centrifuged at 300 g for 5 min and the supernatant was discarded. The
pellet was washed twice with PBS and the cells were resuspended in 100 µl PBS and
transferred into FACS tubes. Analysis of the transfected cells was carried out using a
BD LSR II device.
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Figure 3: FACS analysis of A172 cells transfected with Block-iT Alexa
The top left panel shows the total distribution of the cell suspension, where the P1
(parental) area represents the supposed population of living cells. The cells were
distinguished by their size (forward scatter: FSC) and their granularity (side scatter:
SSC). The top right panel is displaying the amount of fluorescent cells out of the P1
area. To visualize Block-iT Alexa, which is a red fluorescent siRNA, a 575 nM laser
was used. The bottom panel shows the distribution of living cells  P1, fluorescent
cells Q1 and non-fluorescent cells Q3.
B.2.9.2 Transfection of miRNA mimics and inhibitors
For modulation of the endogenous miRNA expression, miRNA mimics and inhibitors
were used. These molecules either functionally up-regulate the miRNA expression or
down-regulate the miRNA activity. Mimics are chemically modified double stranded
RNAs that are mimicking endogenous miRNA function and can bind to the target
gene  for  posttranscriptional  repression  of  the  respective  gene.  Inhibitors  are
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chemically  modified,  single  stranded RNAs that  are complementary to the target
miRNA. These inhibitors confer the ability to reduce the endogenous miRNA level,
thus increasing the target gene expression.
Material
 24-well cell culture plates (Greiner)
 DMEM Glutamax (Thermo Fisher) without additives
 Lipofectamine RNAiMAX transfection reagent (Thermo Fisher)
 mirVana miRNA Inhibitor (Thermo Fisher), 20 µM stock
 miRVana miRNA Inhibitor Negative Control #2 (Thermo Fisher), 20 µM stock
 mirVana miRNA Mimic (Thermo Fisher), 20 µM stock
 mirVana miRNA Mimic Negative Control #1 (Thermo Fisher), 20 µM stock
Procedure
To monitor the siRNA presence in the cells over time and to determine the optimal
siRNA concentration,  the cells  were seeded and transfected according to B.1.5.1.
After 24, 48 and 78 hours the cells were lysed and RNA was extracted as described in
B.1.4.
B.2.9.3 Transfection of plasmids
Material
 6-well cell culture plates (Greiner)
 FACS device BD LSR II (BD Biosciences)
 Culture medium DMEM Glutamax (Thermo Fisher), supplemented with 10%
FCS (Sigma-Aldrich) and 1% Penicillin/Streptomycin (Thermo Fisher)
 DMEM Glutamax (Thermo Fisher) without additives
 eSpCas9 1.1 GFP Plasmid, 1 µg/µl stock
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 Lipofectamine transfection 3000 (Thermo Fisher)
 P3000 transfection additive (Thermo Fisher)
 PBS
 Dissociation solution TrypLE Express (Thermo Fisher)
Procedure
The cells were seeded in 6-well plates in amounts between 150,000 and 250,000
cells 24 hours prior transfection. The amount of cells varied depending on the cell
line  to  achieve  a  confluency  of  70-90%  on  the  day  of  transfection.  For  the
transfection mix, two microcentrifuge tubes were prepared for each condition. In the
first tube, 125 µl additive-free DMEM was placed and 3, 5 or 7 µg plasmid DNA and 5
µl P3000 reagent were added. In the second tube, 125 µl additive free-DMEM was
combined with 3.75, 5.6 or 7.5 µl Lipofectamine 3000. Afterwards, 125 µl of the DNA
containing mix was added to the corresponding Lipofectamine tube. The samples
were incubated for 15 min at room temperature and 250 µl of the transfection mix
was added onto the cells. The plates were incubated for four hours. Afterwards, the
cell  culture  medium  was  discarded  and  fresh  medium  was  added  to  the  cells.
Fluorescence-activated  cell  sorting  was  carried  out  24  hours  after  transfection.
Therefore, the culture medium was discarded and the cells were washed with PBS
once. For detachment of the cells, 500 µl TrypLE Express was added to the wells and
the plates were incubated at 37°C for 5 min. The reaction was terminated with 500
µl DMEM, the cells were transferred to a centrifugation tube and the samples were
centrifuged at 300 g for 5 min. The supernatant was discarded and the cells were
washed twice with PBS. Afterwards, the pellet was resuspended in 300 µl PBS and
the suspension was transferred into FACS tubes. Analysis of the transfected cells was
carried out using a fluorescence-activated cell sorter (BD LSR II).
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Figure 4: FACS analysis of U87 cells transfected with eSpCas9 GFP 
The top left panel shows the total  distribution of the cell  suspension, where the
parental (P1) area represents the supposed population of living cells. The cells were
distinguished by their size (forward scatter: FSC) and their granularity (side scatter:
SSC). The top right panel is displaying the amount of GFP expressing cells out of the
P1 area. To visualize GFP a 530 nM laser was used. The bottom panel shows the
distribution of living cells P1, GFP expressing cells Q1 and non-expressing cells Q3.
B.2.10 Single cell cloning 
For the generation of cell clones, the transgenic cells were subjected to single cell
cloning. This task is generally performed by FACS-based approaches or seeding the
cells in increasing dilutions until a theoretical amount of one cell per well is reached.
In this study, the cells were seeded in low density on large cell culture plates. After
sufficient  growth,  distinct  cell  colonies  were individually  removed from the plate
using sterile  filter  paper.  Expansion of  the cells  was done gradually  from 24-well
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plates to 6-well  plates. This technique has the advantage of multiple numbers of
growing cells on a single petri dish thus avoiding cell cloning from a single cell origin.
Material
 24-well cell culture plates (Greiner)
 6-well cell culture plates (Greiner)
 Cell culture dishes 10 cm and 15 cm diameter (Greiner)
 Culture medium DMEM Glutamax (Thermo Fisher), supplemented with 10%
FCS (Sigma-Aldrich) and 1% Penicillin/Streptomycin (Thermo Fisher)
 PBS
 Sterile filter paper (Sigma-Aldrich) cut in circles of approx. 4-5 mm diameter
 Dissociation solution TrypLE Express (Thermo Fisher)
Procedure
For the generation of single clones, the cells were seeded on cell culture dishes in
low density  of  about  125-750 cells  per  plate.  The cells  were grown for  14 days.
Afterwards, the colonies were observed under a microscope and evenly distributed
colonies were designated for further treatment. The culture medium was discarded
and the cells were washed with PBS once. The sterile filter paper was immerged in
TrypLE  Express  and  the  papers  were  placed  directly  onto  the  marked  colonies.
Afterwards, the plates were incubated at 37°C for 5 min. The papers were removed
from the plate and transferred into 24-well containing culture medium. The floating
filter papers were removed from the 24-well plate after 24 hours and the cells were
observed daily. After the cells were grown to a confluency of approx. 80% the cells
were detached from the plates  as  described above.  Afterwards,  the clones  were
transferred into 6-well plates and observed for cell growth and morphology daily.
After  colonies  of  at  least  1000  cells  were  established,  the  single  clones  were
transferred into culture flasks or frozen in liquid nitrogen as described in B.2.1.
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B.2.11 Colony formation assay
Cell survival after irradiation or chemotherapeutic treatment was measured based
on the clonogenic survival of cells. For this experiment, the cells were seeded on
culture dish with increasing cell numbers depending on the irradiation dose or the
concentration of the chemotherapeutic agent. Afterwards, the cells were grown for
14 days  and the colonies were stained and counted.  A major component of  this
experiment is the plating efficiency (PE). This value displays the amount of colonies
grown without treatment and is highly variable between cell lines. Survival of the
cells after treatment was normalized to the PE.
Material
 6-well or 24-well cell culture dishes (Greiner)
 Culture medium DMEM Glutamax (Thermo Fisher), supplemented with 10%
FCS (Sigma-Aldrich) and 1% Penicillin/Streptomycin (Thermo Fisher)
 Dimethyl sulfoxide (DMSO) (Sigma-Aldrich)
 Fixation solution 80% ethanol (Merck), 0.3% methylene blue (Sigma-Aldrich)
 RS225 irradiation chamber (X-Strahl)
 Temozolomide (TMZ) (Tocris) dissolved in DMSO with a stock concentration
of 50 µM
Procedure
For the determination of the clonogenic survival upon irradiation or temozolomide
treatment, the cells were seeded in 6-well or 24-well plates. The number of cells per
well  varied between 50-500,000 cells depending of the size of the plate and the
respective treatment. Generally, approximately 50 colonies per well were suitable
for evaluation of the clonogenic growth. After seeding of the cells, attachment of
cells was allowed for 4 h, medium was changed, and cells were irradiated at 0, 1, 2,
4, 6, or 8 Gy, respectively. Three independent experiments were performed per cell
line.
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Clonogenic survival  upon TMZ treatment was determined accordingly.  Four hours
after seeding, medium was exchanged, and TMZ was added to a final concentration
of 0, 5, 10, 50, 100, 200, or 500 µM respectively. 24 hours later,  TMZ-containing
medium was removed and fresh, TMZ-free medium was added. After 14 days cells
were fixed with 80% ethanol solution containing 0.3% methylene blue followed by
extensive washing in deionized water and air-drying.  Colonies of  at  least  50 cells
were  counted  using  a  binocular  or  a  light  microscope.  The  experiment  was
conducted  in  triplicates  and  several  persons  determined  the  cell  number.  The
surviving fractions (SFs) for each condition were calculated by normalizing on the
determined plating efficiency.
Figure 5: Stained colony formation assay using LN18 cells
Pictures  show the stained plates  from the top of  the plate.  The grown colonies
appear as blue dots on the surface of the respective wells. 100 cells were seeded per
well.
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B.2.12 Assessment of the MGMT promoter methylation status
Material
 Promega M16 Blood DNA purification kit
Procedure
Assessment  of  the  MGMT  promoter  methylation  status  was  performed  in
collaboration with Dr.  Viktoria Ruf  from the Center of  Neuropathology and Prion
Research of the LMU University Hospital Munich. The sample DNA was isolated from
cell  suspensions  on  a  Maxwell®  16  MDx  instrument  using  the  M16  Blood  DNA
purification  kit  according  to  manufacturer’s  instructions.  DNA  concentration  was
assessed using a NanoDrop1 ND-1000 Spectrophotometer.
The MGMT promoter methylation status was assessed by MSP PCR and sequencing.
After sodium bisulfide treatment of the DNA, MSP PCR was performed using primers
specific  for  methylated  or  unmethylated  DNA and  PCR  products  were  visualized
using the FlashGelTM System. For bisulfide sequencing, a 316 bp fragment with 25
CpG sites of the MGMT promoter region was amplified after bisulfide treatment.
Sequencing of purified PCR products was subsequently performed on an ABI3130
sequencer. The MGMT promoter sequence was considered ‘methylated’ if ≥ 13 of
the 25 CpG sites showed methylation specific peaks, i.e. at least 50% signal intensity
of the corresponding thymine peak. 
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B.3 qPCR
A quantification of the expressed miRNAs was carried out by qPCR analysis using the
Qiagen miScript II System. It is based on a polymerase chain reaction in combination
with a fluorescent dye, which incorporates with double-stranded DNA and acts as a
reporter  for  quantification  of  the  produced  amount  of  DNA.  Additionally,  a
background  fluorescent  dye  is  added  that  is  used  for  normalization  (ROX).  The
miScript II  System utilizes the SYBR green technology that  interacts unspecifically
with  double  stranded  DNA.  At  the  same  time,  ROX  is  used  for  normalization
purposes.  To  generate  constructs  suitable  for  PCR analysis,  the miRNAs  are  first
polyadenylated. Subsequently, an oligo-dT primer with a universal tag is ligated to
the  3’-end  of  the  miRNAs  (Figure  6).  Afterwards,  the  RNA  undergoes  a  reverse
transcription reaction to generate cDNA. In the following PCR reaction, the mature
miRNA sequence acts as the binding site for  the miRNA specific forward primer,
whereas the universal tag acts as the binding site for the unspecific reverse primer.
As an indicator for the produced DNA, threshold cycle (CT) values were analyzed. The
CT value correlates to the PCR cycle where the reporter fluorescence is significantly
higher than the background signal. For a relative quantification, the CT values of the
target genes were normalized to the CT values of endogenously expressed RNA. In
this study, small nucleolar RNAs (snoRNAs) were used for normalization. After the
PCR cycles were completed, a melting curve analysis was added to the PCR protocol.
A single melt curve peak indicates that a pure PCR product was produced whereas
multiple peaks indicate secondary PCR products.  To ensure reproducibility of  the
qPCR experiment, a single PCR product is required. To optimize the PCR and to avoid
secondary products, the efficiency of the used primers was analyzed and the optimal
cycling conditions were determined.
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Figure 6: Selective conversion of mature miRNAs into cDNA
In the reverse transcription reaction, mature miRNAs are polyadenylated (A) and an
oligo-dT primer with universal tag is ligated to poly-A tail (B). The oligo-dT primer is
used for creating double stranded cDNA out of the single stranded miRNA sequence
(C).  In  the qPCR reaction,  the forward primer  binds  to  the miRNA sequence for
synthesis of the first PCR product (D). In subsequent PCR cycles, the forward miScript
primer and the reverse universal primer are utilized for synthesis of DNA molecules
(E).
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B.3.1 qRT-PCR
Material
 Nanodrop Spectrophotometer ND1000 (Nanodrop Technologies)
 10x miScript PCR Control RNU6 (Qiagen)
 10x miScript PCR Control SNORD-61 (Qiagen)
 10x miScript PCR Control SNORD-68 (Qiagen)
 10x miScript PCR Control SNORD-95 (Qiagen)
 10x miScript primer assay hsa-let-7a-5p (Qiagen)
 10x miScript primer assay hsa-let-7b-5p (Qiagen)
 10x miScript primer assay hsa-miR-125a-5p (Qiagen)
 10x miScript primer assay hsa-miR-615-5p (Qiagen)
 96-well PCR plates (ThermoFisher)
 GeneAmp PCR System 9700 (Applied Biosystems)
 MicroAmp Optical 384-Well Reaction Plate (Applied Biosystems)
 MicroAmp Optical Adhesive Film (Applied Biosystems)
 miScript SYBR Green PCR Kit (Qiagen)
10x miScript universal reverse primer
2x QuantiTect SYBR Green PCR Master Mix
RNase-free water
 Qiagen miScript II reverse transcription Kit (Qiagen)
miScript Reverse Transkriptase Mix
10x miScript Nucleics Mix
5x miScript HiSpec reverse transcription buffer
RNase-Free Water
 Viia 7 Real-Time PCR System (Applied Biosystems)
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Procedure
Quantification of purified DNA or RNA is carried out using a Nanodrop device at a
wavelength of 260 nm. The instrument is calibrated using 1 µl H2O and measurement
of the nucleic acids is performed using 1 µl of the sample. Purity of DNA or RNA is
measured using the ratio of the absorption at 260/280 nm and 260/230 nm. Pure
DNA shows a 260/280 ratio of >1.8 and pure RNA shows a ratio of >2.0. The resulted
concentrations are received in ng / µl.
For the reverse transcription reaction, the HiSpec buffer was utilized to specifically
transcribe mature miRNAs. The sample preparation was performed on ice under a
sterile laminar flow bench that was designated for working with RNA. In a 96-well
PCR plate, 10 ng RNA in 2.4 µl RNase-Free water was added to 0.8 µl 5x HiSpec buffer
mixed with 0.4 µl Nucleics Mix and 0.4 µl Reverse Transcriptase Mix. The samples
were incubated on a GeneAmp PCR System at 60°C for 60 min and at 95°C for 5 min.
Afterwards, the reaction was cooled to 4°C and diluted with 16 µl RNase-free water
to a total volume of 20 µl. The resulting cDNA was stored at -20°C. 
For  each  reaction,  5  µl  QuantiTect  PCR Master  Mix  was  mixed with  1  µl  of  the
respective miScript Primer assay, 1 µl of the universal reverse primer and 2 µl RNase-
free water. The master mix was dispersed into designated wells of a 384-well plate.
Afterwards, 1 µl of the diluted cDNA was added to each well. The plates were sealed
with MicroAmp Optical film and the samples were vortexed and centrifuged. PCR
was performed on a Viia 7 device. For setting up the experiment, the Viia 7 software
was utilized. The following cycling conditions were applied:
95°C for 15 min
94°C for 15 sec
55°C for 30 sec
70°C for 30 sec
These steps were repeated for 40 cycles
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B.3.2 Determination of optimal PCR conditions
Analysis of the primer efficiency
An optimal performance of the involved primes is crucial for generating reproducible
data. Determination of the efficiency of the respective primer pairs was done by a
standard  curve experiment.  Therefore,  prepared cDNA as  described in  B.2.2  was
diluted in 1:5 ratios in RNase-free water. For each primer pair, five data points in
triplicates were generated. The PCR was conducted as described in B.2.3. In the Viia
7  software,  the  option  “Standard  curve  experiment”  was  selected.  Slope  of  the
resulting curves  was  retrieved from the  results.  All  primer  pairs  had  to  have  an
efficiency of >95%. The efficiency was calculated as:
E=10−1/m−1
E: Efficiency of the primer 
m:  Slope  of  the  standard  curve.  The  slope  is  calculated  from  the  vertical  and
horizontal difference of two points of a line.
Determination of the optimal primer concentration
For primer pairs that did not show >95% efficiency, a primer matrix was created. For
this purpose, the 5 µM stock primers were diluted to 2.5 µM, 1 µM and 500 nM and
all possible combinations of forward and reverse primer concentrations were applied
in the PCR reactions. The PCR was conducted as described in B.3.1. The resulting C T
values  were  plotted  against  the  ΔRn  values.  The  ΔRn  value  represents  the
normalized reporter signal minus the background signal and reflects the magnitude
of the specific signal generated from a given set of PCR conditions. The primer sets
showing  a  combination  of  highest  ΔRn  value  and  lowest  CT,  were  subjected  to
standard curve analysis as described above.
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B.4 Analysis of global gene expression
To characterize the global gene expressions of the GBM cell lines, gene expression
microarray analysis and RNA sequencing was utilized in this study. Microarrays are a
hybridization-based  approach  that  typically  consists  of  fluorescent-labeled  cRNA
binding to oligos spotted on a glass slide. Microarrays are a well-developed approach
with  a  fast  and  standardized  workflow  for  generation  of  expression  data.  The
drawback  of  microarrays  is  relying  on  known  sequences  and  the  difficulty  of
analyzing FFPE derived RNA. RNA sequencing has risen in popularity in the recent
years,  with  the  advantage  of  characterizing  different  species  of  transcripts  from
mRNA  to  non-coding  RNA  and  small  RNAs  and  not  relying  on  previous  known
sequences  (Wang et al., 2009). Also, RNA sequencing is suitable for analyzing FFPE
derived RNA. The principle of microarray analysis usually involves conversion of total
sample RNA into cDNA. Afterwards, fluorescent-labeled cRNA is transcribed from the
cDNA. The cRNA is then hybridized with the microarray slides overnight. Here, the
cRNA binds to the corresponding probes on the array. After washing of the slides,
the microarrays are analyzed in a slide scanner that creates high-resolution images
of the arrays. For evaluation of the microarray experiment, the fluorescent intensity
of  the  sports  are  correlated  to  the  corresponding  probes.  Higher  fluorescent
intensities reflect higher gene expression and vice versa.
B.4.1 Qubit measurement
RNA concentrations were determined using a Qubit device. The Qubit technology
utilizes fluorescent dyes that bind specific to RNA, DNA or Protein. In this study the
RNA broad range (BR) Kit was used for RNA concentrations more than 20 ng/µl or
the RNA high sensitivity (HS) Kit for concentrations below 20 ng/µl.
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Material
 Qubit 4 Fluorometer (Thermo Fisher)
 Qubit RNA BR or HS Assay Kit (Thermo Fisher)
Qubit RNA Buffer
Qubit RNA Reagent
Qubit RNA Standard #1
Qubit RNA Standard #2
Procedure
Before  the  measurement  was  started,  all  reagents  were  brought  to  room
temperature. For the two standards and all samples a working solution was prepared
combining 199 µl RNA Buffer and 1 µl RNA Reagent. From each sample, 1 µl was
used in addition to 199 µl  working solution. Additionally,  10 µl  of  the respective
standard was combined with 190 µl working solution. The tubes were mixed and
incubated at room temperature for 2 min. Afterwards, the sample concentration was
assessed using a Qubit 4 device according to the manufacturer’s manual using the
respective RNA broad range or high sensitivity program.
B.4.2 Bioanalyzer measurement
For the determination of RNA integrity, a bioanalyzer measurement was conducted.
The Bioanalyzer uses a capillary electrophoresis (CE) principle for size separation of
the nucleic acids. Typically, 12 nucleic acid samples can be analyzed on a single chip
within  30  minutes.  The  chips  are  fabricated  from  glass  and  comprise  an
interconnected network of fluid reservoirs and microchannels, which must be filled
with  a  gel-dye  mixture.  Each  chip  contains  16  wells:  3  for  loading  the  gel-dye
mixture,  1  for  a  molecular  size  ladder,  and  12  for  experimental  samples.  The
movement of nucleic acids through the microchannels is controlled by a series of
electrodes, each of which is independently connected to a power supply. The gel-dye
mixture  consists  of  a  polymer  and  an  intercalating  dye.  Each  experiment  also
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contains a molecular marker for determination of fragment sizes of the nucleic acids
(Panaro et al.,  2000). The quality of the analyzed RNA is displayed using the RNA
integrity number (RIN). The RIN value is based on an algorithm that uses features
from the bioanalyzer experiment. Most importantly, the ratio of the area under the
18S  and  28S  peaks  (Figure  7)  is  calculated  to  the  total  area  under  the  curve
(Schroeder et al., 2006). 
Figure  7: RNA profile of a bioanalyzer measurement using eukaryotic
total RNA
The capillary electrophoresis profile of a successful bioanalyzer run is shown. Clearly
visible are the 18S and 28S peaks whereas the marker peak resembles the smaller
peak at the start of the curve. (Agilent)
Material
 Agilent Bioanalyzer 2100 (Agilent)
 Agilent RNA 6000 Nano Kit (Agilent)
Agilent RNA 6000 Gel Matrix
Agilent RNA 6000 Ladder
Agilent RNA 6000 Nano Marker
Electrode Cleaners
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RNA Nano Chips
RNA Nano Dye Concentrate
Spin filters
 Chip priming station
 RNaseZAP (Ambion)
Procedure
To avoid degradation of the analyzed RNA, the electrodes of the bioanalyzer device
were decontaminated before each experiment. The wells of the electrode cleaner
chip were filled with 350 µl RNaseZAP and the chip was placed in the bioanalyzer
device for 1 min. Afterwards, the chip was replaced with another electrode cleaner
chip containing 350 µl RNase-free water. The chip was placed in the device for 10 sec
and afterwards the electrodes were dried for another 10 sec. 
Furthermore,  the  supplied  RNA  ladder  was  prepared.  Therefore,  it  was  heat
denaturated for 2 min at 70°C. Afterwards, it was cooled on ice and aliquots were
prepared. The aliquots were stored on -80°C until usage. For sample preparation, a
gel matrix was prepared. Therefore, 550 µl RNA 6000 Nano gel matrix was placed
into the top of a spin filter. Afterwards, the tubes were centrifuged for 10 minutes at
1500 g. For creation of the gel-dye mix, 1 µl RNA 6000 Nano dye concentrate was
added to 65 µl of the previously prepared gel. The mix was vortexed thoroughly and
the tubes were centrifuged for 10 min at 13000 g. Afterwards, 9 µl of the gel-dye mix
was pipetted to the bottom of the well marked ‘G’ on the chip. The chip was placed
in a priming station and the plunger of the syringe was pushed down until the clip
held it. After 30 sec, the clip was released and the plunger was allowed to return to
its initial position. Afterwards, 5 µl RNA marker was added to all sample wells. In the
well marked with a ladder, 1 µl of the prepared ladder was added whereas in each
sample well, 1 µl of the corresponding RNA was added. The chip was vortexed and
immediately  analyzed  using  the  Bioanalyzer  2100  device  according  to  the
manufacturers protocol. For data evaluation the RNA Nano program was used.
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B.4.3 Gene expression microarray
Microarrays  are  a  technology  that  allows  the  simultaneous  measurement  of
thousands  of  nucleic  acids  in  parallel.  Typically,  microarrays  consist  of  DNA
sequences (probes) that are covalently attached to a surface, such as a glass slide.
Each probe represents  a  sequence of  interest.  Usually,  RNA samples  are  labeled
using  fluorescent  dyes  and  are  hybridized  to  the  corresponding  probes  during
sample preparation. The probes are clustered in spots on the array and the amount
of  spots  reflect  the  resolution  of  the  array  (Bumgarner,  2013).  In  this  study,
microarrays were used to analyze global mRNA expression of GBM cell lines using
Agilent human 8x60k arrays which allow simultaneous processing of eight samples,
each of which containing approx. 60.000 probes per array. For this, total RNA was
extracted from the cells  and cDNA was prepared.  Afterwards,  labeled cRNA was
synthesized from the cDNA. The cRNA was purified and hybridized to the arrays. The
slides were washed and scanned using an Agilent microarray scanner. Finally,  the
data was exported using the Agilent feature extraction software. An overview of the
sample preparation workflow is displayed in Figure 8.
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Figure 8: Workflow of an Agilent microarray analysis
In  a  microarray  workflow,  the  input  RNA  is  first  converted  to  cDNA  prior
fluorescence labeling, purification and hybridization overnight at 65°C. Afterwards,
the slides are washed and scanned using a microarray scanner. Finally, the data are
exported using the Agilent feature extraction software. The intensity of each spot
reflects expression of  a  gene of  interest.  Higher fluorescent intensities represent
higher gene expression and vice versa.
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Material
 Agilent Microarray Scanner (Agilent)
 DNase/RNase-free water
 Feature Extraction Software (Agilent)
 G3 Human Gene Expression 8 x 60k v3 Microarray Kit (Agilent)
 Gene Expression Hybridization Kit (Agilent)
 Gene Expression Wash Buffer (Agilent)
 GeneAmp PCR System 9700 (Applied Biosystems)
 Hybridization Chamber, stainless (Agilent)
 Hybridization gasket slides (Agilent)
 Hybridization Oven equipped with rotator (Agilent)
 Low Input Quick Amp Labeling Kit, One-Color (Agilent)
 Ozone-Barrier Slide Cover (Agilent)
 RNA Spike-In Kit, One-Color (Agilent)
 RNeasy Mini Kit (Qiagen)
Procedure
Preparation of the Spike-in mix
The spike-in mix was vortexed, incubated at 37°C for 5 min and the tube was spun
down. Four dilutions of the spike mix were prepared in RNase-free water. The first
dilution (1:20) was created using 2 µl spike mix and 38 µl dilution buffer. The tube
was vortexed and the contents  were spun down before  preparation of  the next
dilution. The second dilution (1:25) was prepared using 2 µl first dilution and 48 µl
dilution buffer. The third dilution was prepared using 2 µl second dilution and 38 µl
dilution buffer whereas the fourth dilution (1:2) was prepared using 20 µl of the third
dilution in addition to 20 µl dilution buffer.
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Preparation of the labeling reaction
For labeling of the RNA, 50 ng samples in 1.5 µl nuclease-free water was used. 2 µl of
the spike mix was added to the samples. A T7 primer mix was prepared using 0.8 µl
T7 primer and 1 µl nuclease-free water. The solution was added to the samples and
the tubes were incubated at 65°C for 10 min. Afterwards, the reactions were put on
ice for 5 min. To generate cDNA, 2 µl first strand buffer was added to 1 µl of 0.1 M
DTT and 0.5 nM dNTP mix and 1.2 µl Affinity Script RNase Block Mix. The first strand
buffer was heated for 3 min at 80°C and cooled to room temperature prior use. The
samples were incubated at 40°C for 2 hours and at 70°C for 15 min. Afterwards, the
tubes were placed on ice and the contents were centrifuged briefly. Next, cRNA was
prepared using a T7 polymerase. Therefore, a master mix was produced containing
0.75 µl nuclease-free water, 3.2 µl transcription buffer, 0.6 µl 0.1 M DTT, 1 µl NTP
mix, 0.21 µl T7 RNA polymerase blend and 0.24 µl Cyanine 3-CTP. To each sample, 6
µl master mix was added and the tubes were incubated at 40°C for 2 hours.
Purification of the labeled RNA
For purification of the RNA, the samples were processed using the Qiagen RNeasy
Kit. 84 µl nuclease-free water was added to the tubes and the samples were mixed
with 350 µl  buffer RLT.  The solutions were mixed with 250 µl  100% ethanol  and
transferred onto RNeasy Spin Columns. After centrifugation for 30 seconds at 4°C,
13000 rpm, the flow through and collection tube was discarded and 500 µl buffer
RPE was added to the column. The samples were centrifuged again as described
above and the flow through was discarded. Another 500 µl buffer RPE was added
onto the columns and the tubes were centrifuged for 60 seconds at 4°C, 13000 rpm.
The flow through and collection tube was discarded. To elute the purified RNA, 30 µl
nuclease-free water was added directly on the columns. The samples were incubated
for 60 seconds and centrifuged for 30 seconds at 4°C, 13000 rpm.
Quantification of the cRNA
Quantification of the purified RNA was carried out using a Nanodrop device. The
measurement was performed as described in B.2.1. In the Nanodrop software, the
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options  Microarray  Measurement  and  sample  type  ‘RNA-40’  was  chosen.  The
following  values  were  recorded:  Cyanine  3  dye  concentration  (pmol/µl),  RNA
absorbance ratio (260 nm/280 nm) and cRNA concentration (ng/µl). The yield and
the specific activity of the labeled RNA was determined as:
µgofcRNA=
(ConcentrationofcRNA ) x30 µl (elutionvolume )
1000
PmolCy3 perµgcRNA=
ConcentrationofCy 3
ConcentrationofcRNA
x1000
For further sample preparation, the yield must be of at least 0.825 µg and an activity
of equal or greater than 6.
Hybridization
For  hybridization,  600  ng  of  the  labeled  cRNA  was  mixed  with  5  µl  10x  Gene
Expression Blocking Agent  and 1 µl  25x Fragmentation Buffer.  The samples were
brought to a total volume of 25 µl using nuclease-free water. Afterwards, the tubes
were incubated for 30 min at 60°C and immediately cooled on ice. 25 µl Hi-RPM
buffer was carefully added to the mix by avoiding bubble formation. For loading of
the slides, a clean gasket slide was placed in a hybridization chamber with the label
facing up. Afterwards, 40 µl of the hybridization mix was carefully dispensed onto
the chambers of the gasket slide. It was ensured that the pipette tip did not touch
the surface of the slide or the walls. Any unused wells were filled with 40 µl 1x Hi-
RPM Hybridization Buffer. The microarray slide was gripped on one side and slowly
placed on the gasket slide. The hybridization cover was placed on top of the slide
sandwich and the chamber was closed using the hybridization chamber clamp. The
chamber  was  manually  rotated  to  ensure  all  bubbles  were  moving  freely.  Stuck
bubbles could be moved by gently tapping the chamber on a surface. The chamber
was placed in a rotor of a hybridization oven and the samples were incubated at
65°C, 10 rpm for 17 hours.
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Washing procedure
For washing of the microarrays, dedicated coplin jars for the different solutions and
experiments were used. The hybridization chamber was disassembled and the array-
gasket  sandwich  was  submerged  in  Gene  Expression  Wash  Buffer  1.  While
submerged, the slides were separated and the gasket slide was allowed to drop to
the bottom of the dish. The array was transferred to a slide rack and submerged in
Gene Expression Wash Buffer 1. The slides were incubated for 1 min and the slide
rack was transferred to a third dish containing Gene Expression Wash Buffer 2 at
37°C. After 1 minute, the slide rack was slowly removed from the dish ensuring no
droplets remained on the slide. 
Figure 9: Slide in slide holder for SureScan microarray scanner
(Agilent)
The  hybridized  slide  was  carefully  placed  in  a  slide  holder  (Figure  9)  with  the
“Agilent”-labeled side facing up. Afterwards, an ozone-barrier slide was carefully put
on top of the array. The slide holder was closed and the arrays were immediately
scanned.
Microarray scan and data collection
For scanning of the microarrays, the Agilent Scan Control software was used. In the
software, the settings for one-color scans were chosen (Scan region: 61 x 21.6 mm, 5
µm scan resolution,  5  µm scanning mode: single  pass,  eXtended Dynamix range:
(selected), Dye channel: green, Green PMT: XDR Hi 100% XDR Lo 10%). Afterwards,
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the  images  were  opened  and  the  spots  were  manually  evaluated  for  even
distribution of the signals around the edges and for obvious outliers. 
Microarray data extraction
Extraction of  the  data  into  a  text  file  was  carried  out  using  the  Agilent  Feature
Extraction software (version 11.0.1.1).  The scanned images were loaded into the
program  and  for  data  generation  the  protocol  GE1_1100_Jul11  was  chosen.
Furthermore, the array specific grid template for 8 x 60k arrays was utilized. After
the data was extracted, the quality of each spot was evaluated (Figure 10).
Figure 10: Example of a quality control report for one spot of the 8x60k
microarray, generated by the feature extraction software
Quality report of the gene expression data generated from the A172 cell line. The
utilized  options  of  the  gene  extraction software  are  displayed  in  the  top  panel.
Obvious outliers can be identified in the grid setup displayed below. For correct data
extraction, the grid had to be perfectly aligned to the four corners of the spot.
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B.4.4 3’-RNA sequencing
3’-RNA sequencing is a novel approach to generate gene expression values. In a first
step  libraries  of  sample  RNAs  are  created  that  can  be  sequenced  on  common
platforms such as the Illumina devices. This method uses total RNA as input whereas
the polyadenylation tail of the mRNA is utilized to initiate library generation by oligo-
dT priming. After synthesis of the first strand, the RNA template is degenerated and
second  strand  synthesis  is  initiated  by  random  priming.  Consecutively,  a  DNA
polymerase allows amplification the cDNA.  Afterwards, the cDNA is purified using
magnetic  beads.  Finally,  the  cDNA  library  is  generated  by  amplification  of  the
purified cDNAs. For this step, adapters required for sequencing are introduced on
the forward and reverse primers. 
Material
 Lexogen QUANTSEQ 3’mRNA-Seq Library Prep Kit
First Strand cDNA Synthesis Mix 1
First Strand cDNA Synthesis Mix 2
Enzyme Mix 1
RNA Removal Solution
Second Strand Synthesis Mix 1
Second Strand Synthesis Mix 2
Enzyme Mix 2
PCR Mix
Enzyme Mix 3
I7 Index Plate 
Purification Beads
Purification Solution
Elution Buffer
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Procedure
Library  preparation  and sequencing  was  performed in  collaboration  with  Steffen
Heuer,  Peter  Weber  and  Theresa  Heider  from  the  Research  Unit  of  Radiation
Cytogenetics of the Helmholtz Center Munich. Sample preparation was carried out
using the Lexogen Quant Seq protocol according to the manufacturer’s instructions.
Briefly, 40 ng total RNA was mixed with 5 µl first strand synthesis mix 1 and the
samples were denatured for 3 minutes at  85°C.  Afterwards,  the RNA was cooled
down to 42°C. 
For first  strand cDNA synthesis a mastermix was created using 9,5 µl  first strand
cDNA synthesis mix 2 and 0,5 µl enzyme mix. The mastermix was pre-warmed at
42°C and 10  µl  was  added to  the  samples.  The  reaction was carried out  for  15
minutes at 42°C. Afterwards, the template RNA was removed by addition of 5 µl RNA
removal solution and the samples were incubated for 10 minutes at 95°C and cooled
down to 25°C. 
For synthesis of the second strand, 10 µl second strand synthesis mix 1 was added to
the cDNA and the samples were incubated for 1 minute at 98°C and cooled down to
25°C slowly at 0,5°C/second. Afterwards, the samples were incubated for 30 minutes
at 25°C. A mastermix was created using 4 µl second strand synthesis mix 2 and 1 µl
enzyme mix 2 and 5 µl was added to each sample. The tubes were incubated for 15
minutes at 25°C.
Purification of the cDNA was carried out using magnetic beads. To each reaction, 16
µl resuspended purification beads was added and incubated for 5 minutes at room
temperature. The samples were placed on a magnet and the beads were allowed to
settle on the bottom of the tubes. The supernatant was removed and 40 µl elution
buffer was added to the samples. The tubes were removed from the magnet and
resuspended properly.  Afterwards,  56 µl  purification solution was added and the
samples were incubated for 5 minutes at room temperature. The tubes were placed
on the magnet again and the supernatant was removed. The beads were washed
twice  using  120  µl  80%  ethanol  and  the  beads  were  allowed  to  dry  at  room
temperature.  To  each  tube 20  µl  elution buffer  was  added and  the beads  were
resuspended and incubated for  2  minutes at  room temperature.  Afterwards,  the
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tubes were placed on the magnet again and 17 µl purified sample was transferred
into fresh PCR plates. 
Finally,  the  cDNAs  were  amplified  by  adding  adapter  sequences  required  for
sequencing. A mastermix was prepared using 7 µl PCR mix and 1 µl enzyme mix 3
and 8 µl was added to each sample. Twenty PCR cycles were performed in according
to  the  protocol.  The  finished  libraries  were  purified  using  magnetic  beads  as
described above. The libraries were sequenced using an Illumina HiSeq device at the
core facility of the Helmholtz Center Munich.
B.5 CRISPR-Cas9
For  knockout  of  the mature miRNAs  a  CRISPR-Cas9 system was established.  The
knockout strategy was intended to introduce a double strand break in the mature
miRNA sequence and in  parallel,  to  introduce an expression cassette carrying an
antibiotic resistance gene or a fluorescent protein via homologous recombination.
Therefore, three plasmids had to be transfected in the cells, one carrying the Cas9
endonuclease, one plasmid for expression of the guide RNA and a linearized plasmid
that contains the selection cassette. For this approach,  a Cas9 vector (VP12) was
utilized  that  included  a  Cas9  expression  cassette  that  was  co-transfected  with  a
plasmid for guide RNA expression (MLM3636).  The guide RNAs were designed to
target the genomic location of the mature miRNAs. Additionally, for each miRNA, a
vector  was  constructed  that  carried  1000  bp  overlapping  DNA  sequences
homologous  to  the immediate  upstream and downstream region  of  the miRNAs
attached to an antibiotic resistance cassette and a fluorescent protein. All described
constructs had to be transfected into to the cells for a knockout of one miRNA. 
59
Material and methods
B.5.1 Guide RNA design
For generation of the CRISPR guide RNAs, a tool for design and off-target prediction
was utilized (crispr.mit.edu).  For  this  purpose,  the miRNA genomic  locations and
sequences  were  retrieved  from  the  NCBI  nucleotide  browser
(www.ncbi.nlm.nih.gov/nuccore).  The positions of  the miRNA precursor sequence
including the 1000 bp upstream and downstream regions were downloaded in a text
file.  The  miRNA  precursor  sequences  were  uploaded  in  the  crispr.mit  tool.  The
software assigns scores for possible guide RNAs that reflect the reverse probability of
off-target binding. Only guide RNAs with the highest scores (>80) were subjected to
cloning into the vectors.
B.5.2 Plasmid overview
Three  vectors  were  needed  for  the  CRISPR  approach  of  this  study,  one  plasmid
expressing the Cas9 nuclease (VP12 Figure 11),  one plasmid expressing the guide
RNA (MLM3636 Figure 12) and another plasmid (pFG4-GFP Figure 13) for expression
of the selection cassette. The VP12 plasmid was received from Dr. Rupert Öllinger
(TU  München).  The  plasmid  was  originally  purchased  from  Addgene  (Addgene
plasmid #72247, Kleinstiver et al., 2016) that allows the constitutive expression of
Cas9 using a CMV promoter. MLM3636 was also purchased from Addgene (Addgene
plasmid #43860, unpublished) that carried a cloning site for the introduction of the
target-specific guide sequence. The guide RNA was expressed under control of the
RNA promoter U6. For expression of the selection cassette, the plasmid pFG4-GFP
was used. With support of Randy Caldwell the plasmid was established at HMGU in
the research unit  Radiation Cytogenetics.  The vector carried two cloning sites for
introduction of  the miRNA specific  target  arms.  The construct  included two loxP
recombination sites for optional modification of the integrated plasmid. Two genes
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for selection were part of the vector, GFP and a puromycin resistance gene that were
fused via an internal ribosome entry site (IRES) sequence.
Figure 11: Overview of the Cas9 expression vector VP12
The  features  of  the vector  are  displayed  simplified.  The  vector  carried  the Cas9
expression cassette under control of a constitutive CMV promoter for expression in
mammalian cells. For bacterial transformation and selection, an ampicillin resistance
gene was present in the vector.
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Figure 12: Overview of the guide RNA expression vector MLM3636
The features of the vector are displayed in a simplified scheme. The vector carried a
cloning site for introduction of the target specific guide sequence. The guide RNA
was expressed under control of the RNA promoter U6. Furthermore, for bacterial
transformation  and  selection,  an  ampicillin  resistance  gene  was  present  in  the
vector.
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Figure  13: Overview of the selection cassette expression vector pFG4-
GFP
The features of the vector are displayed in asimplified scheme. The vector carried
two cloning sites for introduction of the miRNA specific target arms. The construct
included two loxP recombination sites for optional modification of the integrated
plasmid.  Two  genes  for  selection  were  part  of  the  vector,  GFP  and  puromycin
resistance  gene  fused  via  an  IRES  sequence.  Furthermore,  for  bacterial
transformation  and  selection,  an  ampicillin  resistance  gene  was  present  on  the
vector.
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B.5.3 Plasmid linearization and purification
Material
 BsmBI (NEB)
 GeneJET PCR purification Kit (Thermo Fisher)
DNA Binding buffer
Wash buffer (100% ethanol added prior use)
Elution buffer
GeneJET Purification Columns
 Centrifuge Biofuge pico (Heraeus)
 RNase/DNase-free water
 Alkaline Phosphatase, Calf Intestinal (CIP) (NEB)
 BamHI-HF (NEB)
 NEBuffer 3.1
Procedure
For  linearization  of  the  plasmids,  MLM3636  was  digested  using  the  restriction
enzyme BsmBI at  55°C,  pFG4-GFP was digested using BamHI-HF at  37°C.  For the
reaction, 20 µl of the plasmid was added to 5 µl NEBuffer 3.1, 23 µl RNase/DNase-
free water and 2 µl  of the respective enzymes.  The reaction was incubated over
night at the respective temperatures. To avoid self ligation of the plasmids, 1 µl CIP
was added to each reaction and the vectors were incubated at 37°C for one hour.
Afterwards, 50 µl binding buffer was added to each reaction and the mixture was
transferred onto a GeneJET purification column. The samples were centrifuged at
12000 g for 1 min and the flow through was discarded. Afterwards,  700 µl  wash
buffer was added to the columns and the samples were centrifuged at 12000 g for 1
min. The flow through was discarded and the columns were centrifuged again to dry
the membranes. To elute the DNA, 35 µl elution buffer was added directly on the
membranes and the samples were incubated for 1 min. Afterwards,  the columns
were centrifuged at 12000 g for 1 min and the DNA concentration was measured
using a Nanodrop device as described in B.3.1. 
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B.5.4 Gibson cloning
Gibson cloning is an alternative technique that allows vector/insert cloning without
the need of specific restriction enzymes. It can also be used for sequential cloning of
multiple fragments in one step. The protocol requires overlapping DNA fragments
and utilizes a 5’ exonuclease, a DNA ligase and a DNA polymerase for combining the
fragments (Gibson et al., 2009).
Material
 100 mM dATP (NEB)
 100 mM dCTP (NEB)
 100 mM dGTP (NEB)
 100 mM dTTP (NEB)
 100 mM NAD (NEB)
 1M DTT (Sigma-Aldrich)
 1M Tris-HCl pH 7.5 (Sigma-Aldrich)
 2M MgCl2 (Sigma-Aldrich)
 PEG-8000 (Sigma-Aldrich)
 Phusion DNA polymerase (NEB)
 T5 exonuclease (NEB)
 Taq DNA ligase (NEB)
Procedure
On a first step, a 5x ISO buffer was created:
3 ml 1M Tris-HCl pH 7.5
150 µl 2M MgCl2
60 µl of each 100 mM dNTPs (dGTP, dCTP, dATP, dTTP)
300 µl 1M DTT
1.5 µg PEG-8000
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300 µl 100 mM NAD
up to 6 ml dH2O
The 5x ISO buffer was divided in 320 µl aliquots and stored at -20°C.
In a second step, the Gibson assembly master mix was produced:
320 µl 5x ISO Buffer
0.64 µl 10U/µl T5 exonuclease
20 µl 2U/µl Phusion polymerase
160 µl 40U/µl Taq polymerase
699 µl dH2O
The Gibson master mix was stored at -20°C in 15 µl aliquots. For each reaction one
aliquot is used. 
B.5.4.1 PCR-amplification of the homologous arms
Material
 10 mM dNTP Mix (Fermentas)
 10x Crezol Red
 5x Q5 reaction buffer (NEB)
 100 µM Primer (B.4.11) (Sigma-Aldrich)
 Agarose gel (1-2%)
 Centrifuge Biofuge pico (Heraeus)
 DMSO (NEB)
 GeneAmp PCR System 9700 (Applied Biosystems)
 GeneJET PCR purification Kit (Thermo Fisher)
DNA Binding buffer
Wash buffer (100% ethanol added prior use)
Elution buffer
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GeneJET Purification Columns
 Q5 high fidelity DNA polymerase (NEB)
 TE buffer
 U87-MG genomic DNA
Procedure
The amplification of the homologous arms was carried out using purified U87-MG
genomic DNA. The primers used are displayed in B.4.11 and one primer pair was
designed for each 5’- and 3’-arm for the respective miRNAs. 
The PCR setup was as following:
10 µl Q5 reaction buffer
5 µl Crezol Red
1 µl 10 mM dNTPs
1 µl DMSO
1 µl 25 µM forward primer
1 µl 25 µM reverse primer
0.5 µl Q5 high fidelity DNA polymerase
29.5 µl H2O
The following PCR program was used:
98°C for 30 sec
98°C for 10 sec
60°C for 20 sec
72°C for 60 sec
These steps were repeated for 35 cycles
72°C for 120 sec
4°C hold
The resulting PCR products were analyzed on an 1% agarose gel (90V, 45min). The
DNA fragments with the correct size (approx. 1000 bp) were removed from the gel
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and the samples were purified using the GeneJET PCR purification Kit as described in
B.5.3.
B.5.4.2 Ligation and transformation 
Material
 100 µM Primer (B.4.11) (Sigma-Aldrich)
 E. coli-DH5α (NEB)
 Gibson master mix
 Guide RNA Primers 
 LB agar plates containing ampicillin 
 Linearized vectors
 PCR products of the homologous arms
 SOC outgrowth medium (NEB)
 STE buffer
 Viia 7 (ThermoFisher)
Procedure
For cloning of the guide RNA, two primer for each miRNA (details of the used primers
displayed  in  B.4.11)  were  annealed  in  a  thermocycler.  Therefore,  2  µl  of  each
forward and reverse primer was added to 2 µl STE buffer and 14 µl H 2O. The mixture
was incubated in a Viia 7 machine at 95°C for 5 min and afterwards the temperature
was decreased by exactly 1°C per 30 sec down to 25°C. The primer duplexes were
diluted 1:500 (to approx. 0.02 pmol) using H2O. For Gibson cloning, the linearized
vectors  and  the  inserts  were  mixed  in  equimolar  amounts  using  the  following
formula:
pmols=(weight ng ) x 1,000/ (basepairs x 650daltons )
For each ligation, a 15 µl  Gibson master mix aliquot was thawed and 5 µl of the
equimolar vector/insert mixture was added. The samples were incubated at 50°C for
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60 min. For transformation of the ligation mix in  E. coli-DH5α, the bacteria were
thawed on ice for 30 min. Afterwards, 2 µl of the ligation mix was added to 25 µl of
the E. coli suspension. The bacteria were heat-shocked at 42°C for exactly 45 sec and
the tubes were placed on ice for 2 min. 500 µl SOC outgrowth medium was added to
the samples and the bacteria were incubated at 37°C for one hour. Afterwards, the
suspension  was  plated  on  pre-warmed  LB  agar  plates  containing  ampicillin.  The
plates  were  incubated  at  37°C  over  night.  Single  colonies  were  picked  and
transferred into 96-well  plates containing 100 µl  LB medium with ampicillin.  The
bacteria were incubated over night and the clones were analyzed as described in
B.5.9.
B.5.5 Small scale plasmid preparation
Material
 Centrifuge Biofuge pico (Heraeus)
 GeneJET Plasmid Miniprep Kit (Thermo Fisher)
Resuspension solution with RNase
Lysis Solution
Neutralization Solution
Wash Solution with 100% ethanol
Elution Buffer
GeneJET Spin Columns
Collection Tubes 2 ml
Procedure
For  plasmid  preparation,  50  µl  of  the  picked  clones  were  transferred  into
centrifugation tubes containing 2 ml LB medium with ampicillin. After incubation at
37°C  over  night,  the  cultures  were  transferred  into  2  ml  Eppendorf  tubes  and
centrifuged at 8000 rpm for 2 min. 250 µl resuspension solution was added to the
pellet and the tubes were mixed until the bacteria were resuspended. 250 µl lysis
buffer  was added to the suspension  and the reaction was stopped using  350 µl
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neutralization buffer.  The  tubes  were  centrifuged at  12000  g  for  5  min  and the
supernatant  was  transferred  onto  a  GeneJET  spin  column.  The  samples  were
centrifuged at 12000 g for 1 min and the column was washed twice using 500 µl
wash buffer. For each wash step, the samples were centrifuged at 12000 g for 1 min
and the flow through was discarded.  The column was centrifuged once more to
remove residual  ethanol.  Afterwards,  50 µl  elution buffer  was pipetted onto  the
membrane  and  the  samples  were  incubated  for  2  min.  To  elute  the  DNA,  the
columns were centrifuged for 2 min and the concentration of the DNA was measured
using a nanodrop device as described in B.3.1.
B.5.6 Large scale plasmid preparation
Material
 Centrifugation cups
 Centrifuge Multifuge 3 S-R (Heraeus)
 Centrifuge pico (Heraeus)
 Chloroform (Merck)
 Ethanol 70% (Merck)
 Falcon Tubes 50 ml (BD Falcon)
 Isopropanol (Merck)
 LyseBlue reagent (Qiagen)
 Qiagen Plasmid Purification Maxi Kit (Qiagen)
Resuspension buffer P1
Lysis buffer P2 (LyseBlue reagent added)
Neutralization buffer P3
Column equilibration buffer QBT
Wash buffer QC
Elution buffer QF
 TE buffer
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Procedure
For  generation  of  larger  amounts  of  plasmids,  400  ml  LB  medium  containing
ampicillin was inoculated with bacteria grown from one colony. The cultures grew
overnight  and  the  suspension  was  transferred  into  a  centrifugation  vessel  and
centrifuged at 4000 rpm for 30 min. The supernatant was discarded and the pellet
was  resuspended  in  10  ml  buffer  P1  and  transferred  into  50  ml  falcon  tubes.
Afterwards, 10 ml buffer P2 was added and the samples were incubated for 5 min.
The reaction was stopped by adding 10 ml buffer P3 and the samples were incubated
on ice for 20 min. Afterwards, 750 µl cooled chloroform was added to the samples
and  the  tubes  were  centrifuged  at  4000  rpm  4°C  for  30  min.  Meanwhile,  the
purification  columns  were  equilibrated  using  10  ml  buffer  QBT  and  10.5  ml
isopropanol was placed in a 50 ml elution tube. After centrifugation, the supernatant
was carefully transferred onto the purification columns, avoiding carry over of cell
debris. The columns were washed twice with wash buffer QC and the plasmids were
eluted into the prepared elusion tube using 15 ml elution buffer QF. The tubes were
mixed thoroughly and centrifuged at 4000 rpm 4°C for 30 min. The supernatant was
carefully  discarded  and  the  pellet  was  washed  with  1  ml  70%  ethanol  and
centrifuged again at 4000 rpm 4°C for 5 min. The supernatant was discarded and the
pellet was air  dried for 30 min. Afterwards,  300 µl  TE buffer was added and the
samples were resuspended over night at 4°C. The DNA concentration was measured
as described in B.2.1 and the plasmids were diluted to a final concentration of 1 µg /
µl.
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B.5.7 Screening of positive clones
B.5.7.1 Restriction analysis
Material
 Agarose gel 1%
 Restriction enzyme BamHI-HF (NEB)
 Purified plasmids
 NEBuffer 3.1
 RNase/DNase-free water
 TE buffer
Procedure
The correct assembly of the pFG4-GFP plasmid with homologous arms was analyzed
by restriction enzyme digest. Therefore, 5 µl of the purified plasmid as described in
B.4.7 was mixed with 2 µl NEBuffer 3.1, 0.2 µl BSA, 1 µl BamHI-HF and 11.8 µl H2O.
The  samples  were  incubated  for  2  hours  at  37°C  and  the  DNA  fragments  were
analyzed on a 1% agarose gel (90V, 45min).
B.5.7.2 Sanger Sequencing
Material
 96-well PCR plates (Applied Biosystems)
 BigDye Terminator Sequencing Kit (Applied Biosystems)
 DEPC H2O
 DMSO (Sigma-Aldrich)
 DNA sequencer ABI 3730 (Applied Biosystems)
 EDTA 125 mM
 Ethanol 100% and 70% (Merck)
 GeneAmp PCR System 9700 (Applied Biosystems)
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 Primer 100 µl (Sigma-Aldrich) see B.4.12
OS280 forward
MLM3636-rev-seq reverse
 SnapGene software 
Procedure
For  confirmation  of  the  correct  assembly  of  the  produced  plasmids,  Sanger
sequencing was performed. Therefore, 200 ng plasmid DNA was mixed with 0.4 µl
primer, 0.5 µl DMSO, 4.1 µl DEPC H2O, 1 µl BDT Sequencing buffer and 2 µl Ready
Reaction Mix BigDye. The PCR mix was dispersed in 96-wells and the plates were
incubated in a thermo cycler using the following protocol:
95°C for 4 min
95°C for 15 sec
50°C for 10 sec
60°C for 4 min
These steps were repeated for 40 cycles
4°C hold
Afterwards,  2.5  µl  125  mM  EDTA  was  added  to  each  well.  The  plates  were
centrifuged at 4000 g for 2 min and 30 µl 100% ethanol was added to the wells. The
samples  were  incubated  for  15  min  at  room  temperature  and  the  plates  were
centrifuged at 4000 g for 30 min at 4°C. The liquid was removed from the wells by
gently tapping on a paper towel and another 50 µl 70% ethanol was added to the
wells.  Afterwards,  the ethanol  was removed again  by  gently  tapping  on a paper
towel. The plates were centrifuged briefly to collect the contents on the bottom of
the wells and the PCR products were resuspended in 40 µl  H2O. Sequencing was
carried out using an ABI 3730 DNA sequencer at the GAC (Genome Analysis Center)
of the Helmholtz Center Munich. The resulting sequence information was analyzed
using the SnapGene software.
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B.5.8 T7 endonuclease assay
T7 endonuclease assay was used for identification of successful knockout events in
transfected  cell  pools.  The  assay  utilizes  an  enzyme  that  specifically  cuts  DNA
mismatches. Briefly, PCR was performed that amplified a region of interest where
base  pair  modification  was  expected.  The  PCR  products  were  denatured  and
reannealed which created heteroduplexes of wild type and knockout PCR products.
These  heteroduplexes  contained  bulges  that  were  cut  by  the  T7  endonuclease,
creating  two  short  fragments.  Afterwards,  the  samples  were  analyzed  using  an
agarose gel. In the case of a successful knockout, one large band and two smaller
bands were visible on the gel (Figure 14).
Figure 14: Schematic overview of the T7 endonuclease assay
The protocol required transfected cells with introduced genomic modifications (A).
Genomic DNA was extracted from the cells (B) and a PCR was performed spanning
the  site  of  the  desired  modifications  (C).  The  PCR  products  contained
heterogeneously wild type and knockout sequences.  The fragments were heated
and realigned forming DNA heteroduplexes (D). T7 endonuclease specifically cleaves
DNA mismatches that resulted in fragmentation of the knockout PCR products (E).
The size differences were visualized on an agarose gel (F) (modified from Wyvekens
et al., 2015).
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Material
 10 mM dNTP Mix (Fermentas)
 10x Crezol Red
 5x Q5 reaction buffer (NEB)
 100 µM Primer (Sigma-Aldrich)
7a-fwd-2 (Table 3)
7a-rev-2 (Table 3)
7b-fwd-2 (Table 3)
7b-rev-2 (Table 3)
125a-fwd-1 (Table 3)
125a-rev-1 (Table 3)
 Agarose gel 2%
 Centrifuge Biofuge pico (Heraeus)
 DMSO (NEB)
 GeneAmp PCR System 9700 (Applied Biosystems)
 NEBuffer 2 (NEB)
 Q5 high fidelity DNA polymerase (NEB)
 T7 endonuclease I (NEB)
 TE buffer
  Viia 7 PCR device (Thermo Fisher)
Procedure
Cells were co-transfected using one of the cloned MLM3636 plasmids for let-7a-1,
let-7b and miR-125a targeting and the VP12 plasmid. Transfection of the cells was
performed as  described in  B.1.7.3.  After  48 hours,  the cells  were harvested and
genomic  DNA was  isolated  as  described  in  B.2.4.  For  each  target  site,  one  PCR
reaction was performed in addition to a negative transfection control and a negative
PCR control:
10 µl genomic DNA template
10 µl Q5 reaction buffer
75
Material and methods
5 µl Crezol Red
1 µl 10 mM dNTPs
1 µl DMSO
1 µl 25 µM forward primer
1 µl 25 µM reverse primer
0.5 µl Q5 high fidelity DNA polymerase
20.5 µl H2O
The following PCR program was used:
98°C for 30 sec
98°C for 10 sec
72°C for 20 sec ramp down 1°C per cycle to 62°C
72°C for 60 sec
These steps were repeated for 10 cycles
98°C for 10 sec
62°C for 20 sec
72°C for 60 sec
These steps were repeated for 20 cycles
72°C for 120 sec
4°C hold
The PCR reactions were purified using the GeneJET purification protocol as described
in B.5.3 and the DNA concentrations were measured using a nanodrop device as
described in B.2.1. For the generation of DNA heteroduplexes, 200 ng purified PCR
product was mixed with 2 µl NEBuffer 2 and the DNA was denatured and hybridized
in a Viia 7 device using the following protocol:
95°C for 5 min denature
95°C ramp down at 2°C/sec for 5 sec
85°C ramp down at 0.1°C/sec for 10 min
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The samples were put on ice and 1 µl T7 endonuclease was added to the tubes.
Cleavage  of  the  DNA was  performed at  37°C  for  15  min  using  a  GeneAmp  PCR
device. Afterwards, the samples were immediately put on ice and the reaction was
stopped adding 2 µl 0.25M EDTA to each sample. The samples were loaded on a 2%
agarose gel (90V, 45min) and the resulting fragments were analyzed.
B.5.11 Survival of cells after puromycin treatment
A  selection  of  clones  that  carry  a  double  strand  break  in  the  genomic  miRNA
locations and have integrated the selection cassette was performed by antibiotic
treatment. In this assay,  the antibiotic concentration necessary for killing all  non-
transfected cells over the period of one week was analyzed.
Material
 6-well cell culture dishes (Greiner)
 Culture medium DMEM Glutamax (Thermo Fisher), supplemented with 10%
FCS (Sigma-Aldrich) and 1% Penicillin/Streptomycin (Thermo Fisher)
 Microscope (Olympus)
 Puromycin stock 1 mg/ml (Invitrogen)
Procedure
The effect of puromycin on the cells was analyzed by a growth-curve. Therefore, the
cells were seeded in 6-well plates with different concentrations of puromycin. The
final concentrations used were: 0 µg/ml (control), 0.25 µg/ml, 0.5 µg/ml, 0.75 µg/ml,
1 µg/ml, 2 µg/ml and 5 µg/ml. The cells were observed over a period of one week
and the medium was replaced with fresh medium after 3 days and 5 days. On each
day the cells were observed using a microscope and the fraction of the surviving cells
was analyzed.
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C Results
In  this  thesis  a  prognostic  4-miRNA signature  was  characterized  and the cellular
function of  these miRNAs was analyzed.  The strategy of  the study was to utilize
seven established in vitro GBM models and to modulate the miRNA expression for
studying mRNA co-expressions enabling an identification of potential targets of the
miRNAs. As a first step, a seven GBM cell line panel was characterized at different
molecular levels and functional phenotypes to find the most optimal model system
for the following experiments. Emphasis was put on cytogenetic and transcriptomic
features of the cell lines as well as various phenotypic properties like the response to
ionizing radiation and TMZ. Afterwards, a transient overexpression and knock down
system for the miRNAs was established and the modulated cell lines were analyzed
by global 3’-mRNA sequencing. Additionally, a stable CRISPR/Cas9 knockout system
was established.
C.1 Cell line characterization
For  the  characterization  of  the  4-miRNA  signature,  a  GBM  cell  line  panel  was
analyzed to find the most optimal cell lines for a functional analysis of the miRNAs of
the  signature  by  using  appropriate  in  vitro  assays.  For  intended  modification  of
miRNA expressions, various features of the cell lines were of special interest like the
complexity  of  the  karyotypes,  the  different  responses  towards  in  vitro  ionizing
radiation  and  TMZ  treatment,  global  gene  expression  profiles  and  the  related
classification into GBM-specific subtypes. Seven of the most prominent cell lines in
GBM research were selected for this thesis and were subsequently characterized:
A172, LN18, LN229, T98G, U87, U138 and U251. After identification of the optimal in
vitro model system, the expression of the 4-miRNAs was modified by transient siRNA
transfection  and  later  by  stable  CRISPR/Cas9  knockout.  In  advance  of
implementation  of  genetic  and  functional  experiments  an  unambiguously
authentication of the selected cell lines was mandatory.
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C.1.1 STR-typing for authentication of the GBM cell lines
The cell lines were obtained from ATCC (A172, LN18, LN229, T98G, U87-MG) and CLS
(U138-MG and U251-MG) in the frame of a collaboration project with Prof. Kirsten
Lauber from the Department of Radiation Oncology of the LMU University Hospital
Munich.  STR-typing  for  analyzing  the  genomic  repeats  of  nine  STR  markers  was
performed  to  verify  to  origin  of  the  cell  lines.  We  found  that  all  analyzed  STR-
markers  (Table  5)  matched  the  corresponding  database  from  the  biorepository
center  “Deutsche  Sammlung  von  Mikroorganismen  und  Zellkulturen  GmbH”
(www.dsmz.de) entries. Notably, the U251-MG cell line shows STR-markers identical
to SNB-19, U373 and TK1 cell  lines which presents an unambiguous identification
(Torsvik et al., 2014).
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Table 5: Overview of the STR-typing of seven glioblastoma cell lines
Cell line Marker AMEL CSF1PO D13S317 D16S539 D5S818 D7S820 TH01 TPOX vWA
A172
Allele 1 X 9 11 12 11 11 6 8 20
Allele 2 Y 12 11 12 12 11 9.3 11 20
LN18
Allele 1 X 12 12 11 11 8 9 8 17
Allele 2 Y 12 13 13 13 10 9 8 18
LN229
Allele 1 X 12 10 12 11 8 9.3 8 16
Allele 2 X 12 11 12 12 11 9.3 8 19
T98G
Allele 1 X 10 13 13 10 9 7 8 17
Allele 2 Y 12 13 13 12 10 9.3 8 20
U87-MG
Allele 1 X 10 8 12 11 8 9.3 8 15
Allele 2 X 11 11 12 12 9 9.3 8 17
U138-MG
Allele 1 X 12 9 12 11 9 6 8 18
Allele 2 Y 12 11 13 11 9 6 8 18
U251-MG*
Allele 1 X 11 10 12 11 10 9.3 8 16
Allele 2 Y 12 11 12 12 12 9.3 8 18
Analyzed alleles according to CODIS (Combined DNA index system) whereas numbers shown represent the individual repeats of the allele. X
and Y depicts whether the respective gonosome is present. Turquoise marker represents matching features as reported in the DSMZ database
(www.dsmz.de). *Other cell lines that show an identical STR-profile including SNB-19, U373-MG and TK-1.
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C.1.2  GBM  cell  lines  harbor  complex  karyotypes  and  structural
aberrations
Spectral  karyotyping  analysis  of  the  individual  karyotypes  was  performed  in
collaboration with Isabella Zagorski from the Research Unit Radiation Cytogenetics at
the Helmholtz Center Munich. The ploidy of the cell lines as well as numerical and
structural  chromosome  aberrations  were  analyzed.  Despite  all  cell  lines  were
anticipated  to  originate  from  the  same  tumor  type,  the  karyotypes  were  highly
variable among the cell lines. Exemplary karyotypes of each cell line are shown in
Figure 15. Clonal aberrations are depicted in Table 6. The ploidy ranged from near-
diploid (U87-MG) to near-hexaploid (T98G). Additionally, subclones were present in
A172, LN18, LN229, U87-MG and T98G cell lines while no subclones were identified
in U138-MG and U251-MG cell lines. 
The A172 cell line showed a near-tetraploid karyotype with two subclones present in
the cell  line.  Two subclones were also present in the hypotriploid LN18 cell  line.
LN229  and  T98G  showed  the  highest  ploidy  with  a  hypotetraploid  and
hypohexaploid karyotype, respectively. Additionally, subclones could be detected in
both cell lines. In contrary, the cell line U87-MG showed a near-diploid karyotype.
Nevertheless, two subclones with different aberrations could be identified in this cell
line as well. Notably, the cell lines U138-MG and U251-MG showed a hypotriploid
karyotype with consistent chromosomal aberrations. Typical chromosomal changes
in GBM are gains in chromosome 7 (Bigner et al., 1988) and loss of heterozygosity in
chromosome 10 (Ohgaki and Kleihues, 2007). Amplifications of chromosome 7 were
found in all cell lines except in U87-MG. In contrary to the loss of heterozygosity,
which was only found in the U87-MG cell line.
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A172 clone 1
LN18 clone 1
LN229 clone 2
A172 clone 2
LN229 clone 1
T98G
A
LN18 clone 1B
C
D
Figure 15: SKY karyotyping of GBM cell lines
Representative karyograms of each cell line after SKY analyses. Each chromosome was displayed in an 
individual false color along with DAPI-banded chromosomes. Color junctions indicate chromosomal
aberrations. The respective karyotypes are described below. 
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A. A172 karyotypes 
71,X,+X,Y,Y,+der(1)t(1;3)(q12;?),+der(1)(1;3)(p12;?),+der(3)t(1;6)(p12;?),+der(2)t(2;5)(q31;?),+3,+der(3)t(3;20)(p12.2;?),
+4,der(5)t(3;5)(?;p11),del(5)(q15)x2,+6,del(6)(q13)x2,+del(6)(q11),+7,+der(7)t(6;7)(?;p13),der(8)t(6;8)(?;p11),
+10,+11,+11,+12,+15,+16,+17,+der(18)t(8;18)(?;q21.1),der(19)t(14;19)(?;q13),+der(19)t(14;19)(?;q13),+20
83,X,+X,Y,+Y,der(1)t(1;14)(p13;?),der(1)t(1;18)(p22;?),+der(1)del(1)(p11)t(1;14)(q21;?),+del(1)(p22;q11),+der(2)t(2;5)
(q31;?)x2,+der(3)(3;9)(q25;?),+5,+der(5)del(5)(q15)t(2;5)(?;p13)x2,+6,+7,+der(7)t(6;7)(q22;?),del(8)(q23),+del(8)(q11),+del(8)
(q13),der(9)t(9;16)(p11;?)x2,+10,+11,+der(11)t(1;11)(?;p11)x2,+12,+12,+13,+der(14)t(9;14)
(?;q13)x2,+15,+16,+16,+16,+17,+der(17)t(17;18)(q11;?),der(18)t(1;18)(?;q21),+der(18)t(1;18)(?;q21),+19,+19,+20,+20,add(21)
(q21),+22
B. LN18 karyotypes 
58,XY,+t(x;10)(q?,q11),+t(x;9)(p?;p?);+t(5;15)(p13;q?),+7,+7,t(6;10)(q11;q?),+t(6;10)(p11;p?),t(1;11)(q?;q?),+t(11;16)(q?;p11),
+del(11)(q11),t(12;16)(q?;p11),+14,+i(1;6)(p10),t(2;17)(p11;q?),t(16;20)(p11;q?),+21,+add(22)(q?)
61,XY,+t(x;10)(q?;q11),+t(x;9)(p?;p?),+3,+t(5;15)(p13;q?),+7,+7,t(6;10)(q11;q?),+t(5;10)(q11;q?),+t(6;10)(p11;p?),+t(10)
(p10),t(11;14)(q?;?),+t(11,18)(q?;q11),+t(12;16)(q?;p11),+20,+t(16;20)(p11;q?)+add22(q?)
C. LN229 karyotypes 
76,XXX,der(X)t(X;2)(q23;?),der(X)t(X;16)(p11;?),+der(X)t(X;19)(p21;?),+1,+der(1)t(1;17)(p32;?),+der(1)t(1;8)(?;q11),
+2,+der(2)t(X;2)(?;q22),+3,+der(3)t(3;5)(q12;?),+der(3)t(3;19)(p12;?),+der(4)t(4;6)(p14;?),+der(4)t(4;9)(q11;?),+der(5)t(5;8)
(q14;?),+der(6)t(6;7)(?;?),+7,+7,+7,i(8)(p10),+der(8)(t8;22)(p22;?),+9,+9,+10,+der(11)t(11;17)(q14;?),+der(12)t(5;12)(?;q15),
+der(12)t(5;12)(?;q12),+13,+der(14)t(14;18)(q24;?),+15,+16,+del(16)(p11),+der(17)t(12;17)(?;q21),+18,+der(19)t(X;19)(?;q12),
+20,+20,+20,+20,+21,+21,+22,+22,+der(22)t(15;22)(?;p12)
D. T98G karyotype
131,XY,+X,+X,+Y,+Y,+Y,+mar trc(7;7;7)(q?;p?;p?)x2,+t(7;8)(q?;p?)x2,+mar dic(10;10)(q?;q?)x1,+i15(q10)
E. U87-MG karyotypes 
44,X,X,t(1)(1:13)(p22;p?)x2,der(6)t(6;7)(p21;p?),der(6)t(6;12)(q23;?),del(7)(q10),del(10)(q21),der(12)t(6;12)(?;q22),-13,-
14,der(16)t(1;16)(?;q13),del(20)(p11),+der(20)t(1;14;20)(?;?;q12),t(22)(10;22)(?;p12)
43,X,-X,t(1)(1;13)(p22;p?)x2,-2,der(6)t(6;7)(p21;p?),der(6)t(6;12)(q23;?),del(10)(q21),del(11)(q11),der(12)t(6;12)(?;q22),-13,-
15,dic(16)(16;16),der(16)t(1;16)(?;q13),del(20)(p11),+der(20)t(1;14;20)(q12;?;?),der(22)t(10;22)(?;p12)
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F. U138-MG karyotype
61-62,XYY,+Y,+der(1)t(1;12)(p31;?),+3,der(4)t(4;17)(q32;?),ins(4)(4;14;4)(p15;?;p13)x2,+7,+der(8)t(8;17)(p21;?),
+der(11)t(11;19)(p13;?),der(12)t(1;12)(?;q14),+13,-14,+15,+18,+der(18)t(6;18)(?;q12),+del(19)(p12),
+20,+20,+22,+der(22)t(5;22)(?;q11)
G. U251-MG karyotype 
66,XXY,+1,+2,+3,+insdic(4;16;4;20)(q12;p11::q?;q?;q?),ins(4)(4;16;4;16)(p?;q?;q?;q?),+5,+7,+7,+iso(8)(q10),
+9,+der(11)t(10;11;15)(q10;q?;q?),+der(11)t(6;10;11)(q?;q?;q?),+15,+17,+17,+del(18)(q12),+19,+20,+21
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Table 6: Overview of cytogenetic characteristics of A172, LN18, LN229, T98G, U87-MG, U138-MG and U251-MG cells
Cell line Predominant clonal karyotype Subclones
A172 83,X,+X,Y,+Y,der(1)t(1;14)(p13;?),der(1)t(1;18)(p22;?),+der(1)del(1)(p11)t(1;14)(q21;?),+del(1)(p22;q11),+der(2)t(2;5)(q31;?)x2,+der(3)(3;9)(q25;?),
+5,+der(5)del(5)(q15)t(2;5)(?;p13)x2,+6,+7,+der(7)t(6;7)(q22;?),del(8)(q23),+del(8)(q11),+del(8)(q13),der(9)t(9;16)(p11;?)x2,+10,+11,+der(11)t(1;11)
(?;p11)x2,+12,+12,+13,+der(14)t(9;14)(?;q13)x2,+15,+16,+16,+16,+17,+der(17)t(17;18)(q11;?),der(18)t(1;18)(?;q21),+der(18)t(1;18)(?;q21),
+19,+19,+20,+20,add(21)(q21),+22
Yes*
LN18 61,XY,+t(x;10)(q?;q11),+t(x;9)(p?;p?),+3,+t(5;15)(p13;q?),+7,+7,t(6;10)(q11;q?),+t(5;10)(q11;q?),+t(6;10)(p11;p?),+t(10)(p10),t(11;14)(q?;?),+t(11,18)
(q?;q11),+t(12;16)(q?;p11),+20,+t(16;20)(p11;q?)+add22(q?)
Yes*
LN229 86,XXX,der(X)t(x;2)(q23;?),der(X)t(X;16)(p11;?),+der(X)t(X;19)(p21;?),+1,del(1)(p10),+der(1)t(1;18)(?;q11),+2,+2,+2,+3,+3,+der(4)t(4;6)
(p14;?)x2,+der(4)t(4;9)(q11;?),+5,+der(5)t(5;12)(p11;?),+der(6)t(6;16)(p13;?)x2,+der(6)t(6;7)(?;?),+7,+7,+der(7)t(5;7)(?;p11)x2,+der(8)t(6;8)(?;q22),
+9,+9,+der(9)t(8;9)(?;q10),+10,+der(11)(q14),+del(12)(q13),+der(14)t(14;18)(q24;?),+16,+16,+del(17)(q12),+18,+der(19)t(X;19)(?;q12),
+20,+20,+20,+21,+21,+22,+22,+der(22)t(15;22)(?;p12)x2
Yes*
T98G 131,XY,+X,+X,+Y,+Y,+Y,+mar trc(7;7;7)(q?;p?;p?)x2,+t(7;8)(q?;p?)x2,+mar dic(10;10)(q?;q?)x1,+i15(q10) Yes*
U87-MG 44,X,-X,t(1)(1:13)(p22;p?)x2,der(6)t(6;7)(p21;p?),der(6)t(6;12)(q23;?),del(7)(q10),del(10)(q21),der(12)t(6;12)(?;q22),-13,-14,der(16)t(1;16)(?;q13),del(20)
(p11),+der(20)t(1;14;20)(?;?;q12),t(22)(10;22)(?;p12)
Yes*
U138-MG 61-62,XYY,+Y,+der(1)t(1;12)(p31;?),+3,der(4)t(4;17)(q32;?),ins(4)(4;14;4)(p15;?;p13)x2,+7,+der(8)t(8;17)(p21;?),+der(11)t(11;19)(p13;?),der(12)t(1;12)
(?;q14),+13,-14,+15,+18,+der(18)t(6;18)(?;q12),+del(19)(p12),+20,+20,+22,+der(22)t(5;22)(?;q11)
No
U251-MG 66,XXY,+1,+2,+3,+insdic(4;16;4;20)(q12;p11::q?;q?;q?),ins(4)(4;16;4;16)(p?;q?;q?;q?),+5,+7,+7,+iso(8)(q10),+9,+der(11)t(10;11;15)(q10;q?;q?),
+der(11)t(6;10;11)(q?;q?;q?),+15,+17,+17,+del(18)(q12),+19,+20,+21
No
The second column describes the predominant clonal karyotype including all chromosomal aberrations. The last column shows whether subclones are
present in the cell lines. The individual karyotypes of the subclones are listed in the supplement (*).
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C.1.3 GBM cell lines response to irradiation and TMZ treatment
To characterize the response towards ionizing radiation and TMZ treatment of the
cells’ clonogenic survival was investigated for each cell line. Therefore, the cells were
irradiated with 0, 1, 2, 4, 6, 8 or 10 Gy and the cells were allowed to grow for 14
days. For TMZ treatment, the cells were incubated in the presence of 0, 25, 50, 100,
200 or 500 µM TMZ for 24 hours. Likewise, the cells were grown for 14 days. 
The resulting response of the cell  lines to irradiation is shown in Figure 16. With
regard to clonogenic survival in a dose range from from 1 to 10 Gy, T98G and U87-
MG cell  line  exhibited the highest  survival  while  the LN229 cell  line  showed the
poorest survival. Pairwise statistical testing using ANOVA of two linear quadratic cell
survival curves (Torsvik et al., 2014), revealed no significant difference for clonogenic
survival between A172, LN18 and U251 cells (Table 7). Also, the survival curves of
LN18 and U138-MG showed no significant difference.
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Figure 16: Clonogenic survival after X-ray irradiation
Survival curves of GBM cell lines irradiated with 1, 2, 4, 6, 8 and 10 Gy. The cells
were treated four hours after seeding and the cells were grown for 14 days before
staining of the colonies. 
This observation allowed the formation of three groups for radioresistance; T98G
and U87-MG which showed the highest resistance, A172, LN18, U138-MG and U251-
MG which showed intermediate resistance and LN229 which was most sensitive. The
survival of the GBM cell lines to TMZ treatment is displayed in Figure 17. The cell
lines LN18, T98G, U138-MG and U251-MG show a significantly higher survival after
TMZ treatment than the cell lines A172, LN229 and U87-MG. As described in A.1.1,
MGMT expression and promoter methylation plays an important role in the outcome
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of TMZ treatment. Therefore, the expression of the MGMT gene was analyzed by
qRT-PCR  in  collaboration  with  Prof.  Kirsten  Lauber.  Additionally,  the  promoter
methylation  status  of  the  MGMT  gene  was  analyzed  by  pyrosequencing  in
collaboration  with  Dr.  Victoria  Ruf  of  the  Institute  of  Neuropathology  at  the
University Hospital of the LMU Munich.
Table 7: Statistical testing using the R package CFassay (Braselmann et al., 2015) of 
the survival curves of the cell lines after irradiation
Cell line 1 Cell line 2 p-value
A172 LN18 0.115706763
A172 LN229 1.82528E-13
A172 T98G 2.52879E-14
A172 U138 0.000325362
A172 U251 0.207081714
A172 U87 2.68299E-08
LN18 LN229 5.55177E-12
LN18 T98G 7.67182E-10
LN18 U138 0.080210882
LN18 U251 0.835961966
LN18 U87 1.40524E-05
LN229 T98G 1.8834E-24
LN229 U138 1.01189E-11
LN229 U251 1.28925E-12
LN229 U87 1.16124E-17
T98G U138 1.98373E-12
T98G U251 4.23232E-10
T98G U87 0.000790985
U138 U251 0.001746446
U138 U87 9.28599E-07
U251 U87 9.5784E-06
The  columns  show the  compared  cell  lines  and the  corresponding  p-value.  Bold
labeled rows depicted a statistical significant difference.
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Figure 17: Clonogenic survival after TMZ treatment
Survival  curves  of  GBM  cells  lines  after  treatment  with  different
concentrations (5, 10, 50, 100, 200 and 500µM) of TMZ. The TMZ treatment
began  four  hours  after  seeding  and  the  TMZ  containing  medium  was
replaced with culture medium after another 24 hours. The cells were stained
after 14 days.
I found MGMT expression in the cell lines LN18, T98G, U138 and U251 (Table 8). The
cell lines A172, LN229 and U87 showed no expression of MGMT. Additionally, the
promoter  was  methylated  in  A172,  LN229,  T98G,  U87  and  U251  cells  while  the
promoter of LN18 and U138 cells was not methylated. Notably, the cell lines T98G
and  U251  showed  MGMT  expression  even  in  the  presence  of  a  methylated
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promoter. Therefore, the observed response to TMZ treatment was more dependent
on the expression of the MGMT gene than on promoter methylation.
Table 8: Overview of the MGMT-promoter methylation, expression of MGMT and 
TMZ resistance of the cell lines
Cell line MGMT-promoter-
methylation
Expression of MGMT
by qRT-PCR
Colony formation assay
upon TMZ treatment
A172 Methylated - More sensitive
LN18 Not methylated 0.62 More resistant
LN229 Methylated - More sensitive
T98G Methylated 0.43 More resistant
U87-
MG
Methylated - More sensitive
U138-
MG
Not methylated 0.61 More resistant
U251-
MG
Methylated 0.17 More resistant
MGMT-promoter methylation data was obtained by pyrosequencing. The Ct values were
created by  qRT-PCR and referenced to 18S  rRNA,  δ-amino-laevulinate-synthase,  and β2-
microglobulin. The MGMT expression of normal human astrocytes was used as calibrator
sample. The response towards TMZ was assessed by colony formation assay. The cell lines
were classified as more resistant if the survival at 10 µM TMZ treatment was greater than
80% and vice versa.
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C.1.4 Expression of the 4-miRNA signature allows assignment of cell 
lines to published risk groups
For the characterization of the 4-miRNA expression in the GBM cell lines, qRT-PCR
was performed. In this study, a SYBR green qRT-PCR system was utilized to measure
the miRNA expression. In a first step, a robust endogenous control for the GBM cell
lines was established. Here, the expression of small nucleolar RNAs RNU6, SNORD61,
SNORD68 and SNORD96 was analyzed (Figure 18) to find a control that is highly and
uniformly  expressed  among  the  cell  line  panel.  Out  of  the  analyzed  controls,
SNORD68 shows the highest expression (median Ct = 21.24) and the most uniform
distribution of Ct values (Figure 18). The other controls had a higher variance and a
lower median expression. The median Ct was 22.45 for RNU6, 23.12 for SNORD61
and 21.54  for  SNORD95.  Afterwards,  the  primer  efficiency  of  the  miRNA-specific
forward primers and the endogenous control in combination with the reverse primer
was analyzed. For optimal thermocycling conditions, the efficiency of each primer
pair  had  to  be  greater  than  95%.  For  this,  a  standard  curve  experiment  was
conducted. Here, previously generated cDNA was diluted in 1:5 ratios to generate
five  data  points.  Afterwards,  qRT-PCR  was  performed  for  each  primer  pair  and
dilution. The resulting Ct values were plotted against the dilution ratio (Figure 19)
and the efficiency was calculated using the slope of the curves as described in B.3.2.
The efficiency of the measured primer pairs was greater than 95% except for the
miR-615-5p  primer.  Therefore,  further  optimization  experiments  had  to  be
conducted as described below.
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Figure 18: Identification of a robust endogenous control for qRT-PCR
Boxplots  displaying  the Ct  values  from the analyzed endogenous controls  RNU6,
SNORD61, SNORD68 and SNORD95. The boxes represent 50% of the variance in the
data set whereas the bold line indicates the median of the data points. The dashed
lines represent the lowest and highest 25% of the data points which is an indicator
for the overall distribution of the data. The Ct values were created from SYBR green
qRT-PCR  using  the  cell  lines  A172,  LN18,  LN229,  T98G,  U87,  U138  and  U251  in
triplicates. 
92
Results
Figure 19: Determination of the qRT-PCR primer efficiency
The standard curves were created using 1:5 dilutions of cDNA. The colors represent
the  individual  primer  pairs  using  the  miRNA-specific  forward  primer  and  the
universal reverse primer. The resulting Ct values were plotted against the dilution
factor. The experiment was conducted in triplicates and five different dilutions were
produced. 
To optimize the efficiency of the miR-615-5p primer within the qRT-PCR reaction, a
primer matrix experiment was performed. For this experiment, the forward and the
reverse primers were analyzed in different concentrations of 1000, 500, 250, 100
and  50  nM  and  qRT-PCR  was  performed  for  each  combination.  The  optimal
combination  of  primer  concentrations  would  yield  the  highest  amount  of  PCR
product  (delta  Rn)  and  the  lowest  Ct  value.  The  delta  Rn  values  and  the
corresponding Ct values were analyzed and thereby the combination of 1000 nM
forward  and  reverse  primer  showed  the  optimal  concentration  (Figure  20).
Afterwards, another standard curve experiment was conducted as described above
to analyze the primer efficiency using the optimized primer concentration (Figure
21).
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Figure 20: Optimal primer concentrations are analyzed using different
combinations of primer concentrations
The results of the primer matrix experiments were created using the miR-615-5p
forward  primer  and  the  universal  reverse  primer.  The  numbers  reflect  the
combination  of  forward  and  reverse  primer  concentration  in  nM.  The  relative
amount of generated PCR product (delta Rn) was plotted against the respective Ct
values. Optimal  primer  combinations  show  a  high  delta  Rn  value  and  a  low  Ct
number (1000/1000, 1000/500, 1000/250). 
94
Results
Figure  21:  Determination  of  the  qRT-PCR  primer  efficiency  after
optimization of the primer concentration
The standard curves were created using 1:5 dilutions of cDNA. The colors represent
the  individual  primer  pairs  using  the  miRNA  specific  forward  primer  and  the
universal reverse primer in concentrations of 1000 nM. The resulting Ct values were
plotted against the dilution factor. The experiment was conducted in triplicates and
five different dilutions were produced. 
After the PCR conditions were optimized, the expression of the miRNAs let-7a-5p,
let-7b-5p,  miR-125a-5p  and  miR-615-5p  were  analyzed  in  the  cell  lines.  The
expression of let-7a-5p was highest in U87-MG cells while the rest of the cell lines
showed comparable expression (Figure 22). This is in contrast to the expression of
let-7b-5p and miR-125a-5p, which was lower in LN229, U138-MG, LN18 and A172
cells than in T98G, U251-MG and U87-MG cells. The expression of miR-615-5p was
highest in U251-MG, U87-MG and A172 and lower in T98G, LN229, U138-MG and
LN18 cells. For alignment of cell lines to patient risk groups that were identified by
the 4-miRNA signature by Niyazi et al. (2016) risk factors were calculated based on
patient-derived risk scores.
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Figure  22: Heatmap of the 4-miRNA expression in the GBM cell lines
and formation of an associated risk factor
The miRNA expression of the cell lines was analyzed by qRT-PCR (bottom panel). The
colors represent higher expression (red) and lower expression (blue) The relative
expression  of  the  miRNAs  compared  to  the  endogenous  control  (SNORD68)  is
displayed. Risk factors were calculated by linear combination based on the patient
derived risk scores (top panel). The dashed line reflects the threshold that allowed
classification of cell lines in low-risk (risk factor was smaller than the threshold) and
high-risk (risk factor was larger than the threshold) groups.
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Briefly,  the survival  of  GBM patients  was  correlated  to  the  expression  of  the 4-
miRNAs. Depending on the influence of the individual miRNA to the survival of the
patients, a risk score could be determined. The relative expression of the 4-miRNAs
was determined in comparison to the endogenous control  SNORD68. Risk factors
were calculated by building the scalar products using the Niyazi  et al.  (2016) cox
proportional hazard model coefficients and signature miRNA expression values. The
following coefficients from model were used:
miRNA Coefficient
Let-7a-5p 0.5059587
Let-7b-5p -0.9669152
miR-125a-5p -0.2821517
miR-615-5p 0.3254795
For classification into high- and low-risk group, the threshold (0.07811832) from the
patient derived model was applied (Niyazi et al., 2016). If the risk factor of the cell
line was higher than the threshold, it was classified as high risk. Likewise, if the risk
score was lower than the threshold, the cell line was considered as low-risk. The risk
factors of the individual cell lines is shown in Table 9. Longer survival was associated
with expression of let-7b-5p and miR-125a-5p while shorter survival was linked to
the expression of let-7a-5p and miR-615-5p. Among the GBM cell lines, A172 had the
highest risk score followed by LN18, U138-MG, LN229, U87-MG, U251-MG and T98G
with the lowest risk score.
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Table 9: Determined risk factors of the GBM cell lines and the corresponding risk 
group
Cell line Risk factor Risk group
T98G -1.783621 Low risk
U251 -0.9891519 Low risk
U87 -0.3347058 Low risk
LN229 0.109434 High risk
U138 0.2791465 High risk
LN18 1.0854292 High risk
A172 1.5121806 High risk
The risk scores were determined  using coefficients from a prognostic model described by
Niyazi et al. (2016) in combination with the signature miRNA expressions. For classification
into a specific risk group the threshold  0.07811832 from the patient cohort was used. Cell
lines with higher risk factors were considered high-risk while cell lines with lower risk factors
were considered low-risk.
Using the described approach  above,  the expression and the related  risk  factors
were calculated for a retrospective GBM patient cohort from the university hospital
of the LMU München. From 37 patients, 17 patients were classified high risk while 20
patients were classified low risk (Figure 23). Overall survival of the patients (Figure
24) was significantly longer for  patients belonging to the low risk  group than for
patients belonging to the high risk group.
98
Results
Figure  23:  Validation  of  the  4-miRNA  signature  by  qRT-PCR  in  a
retrospective LMU cohort
A heatmap of the miRNA expression of a retrospective cohort analyzed by qRT-PCR
is shown. The colors represent higher expression (red) and lower expression (blue)
Risk factors from the patient derived risk scores multiplied by the miRNA expression
are  displayed  in  the  bottom  panel.  The  dashed  line  reflects  the  threshold  that
allowed  classification  of  patients  in  low-risk  (risk  factor  was  smaller  than  the
threshold) and high-risk (risk factor was larger than the threshold) groups.
99
Results
Figure 24: Overall survival of the LMU cohort stratified by the 4-miRNA
signature risk groups
Kaplan-Meier  analysis  according  to  the  risk  groups  generated  by  the  4-miRNA
signature. Low risk patients (yellow) show a significant longer survival than high risk
patients (blue). The number of patients at each time point (years) is depicted at the
bottom of the figure.
C.1.5 Gene expression analysis unveils deregulated pathways among 
the cell line panel
Differences in global gene expression between radiation sensitive and resistant and
TMZ sensitive and resistant cells were analyzed. For this purpose, microarray analysis
was performed to characterize mRNA expression using a 8 x 60k micro array, which
allowed the analysis of eight samples on a single slide with 60,000 probes spotted on
each array. For this experiment, total RNA was isolated from the cell lines and the
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quality of the purified RNA was analyzed using a Bioanalyzer device. The derived RNA
integrity number (RIN), which describes the quality of RNA, showed sufficient (> 7)
scores for all analyzed RNAs (Figure 25) that were considered for microarray analysis.
16S
28S
Figure 25:  Quality  assurance  of  extracted  total  RNA  via  capillary
electrophoresis
RIN  (RNA  integrity  number)  score  represents  a  measurement  for  the  quality  of
analyzed  RNA.  Unfragmented  RNA  shows  distinct  16S  and  28S.  The
electropherograms of  the analyzed RNAs show clearly  visible  16S  and 28S  peaks
(arrows) and high (>9) RIN scores thus being suitable for global gene analysis.
Afterwards,  the RNA was labeled and the slides  were hybridized as  described in
B.4.3. The slides were scanned and the intensities of the spots were exported using
the manufacturers software. An example of a scanned microarray is shown in Figure
26. 
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Figure 26: Scanned 8 x 60k human gene expression micro array
The image shows a scanned 8 x 60k microarray. The format represents eight arrays
on a single glass slide, each harboring 60,000 probes for different transcripts. The
probes were annotated to the NBCI human genome build 38 (GRCh38, December
2013).  The  fluorescence  intensities  correspond  to  the  mRNA  gene  expression
reflected by brightness of the spots.
The micro array  data  has  been deposited at  the NCBI  Gene Expression Omnibus
repository  (Edgar  et  al.,  2002) and  is  accessible  through  GEO  Series  accession
numbers  GSE119468  (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE119468),  GSE119486  (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE119586) and GSE119492 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE119592). Data processing and visualization was performed with support of
Dr.  Kristian Unger  of  the Research  Unit  Radiation  Cytogenetics  at  the Helmholtz
Center Munich. Briefly, the data was filtered and processed using the R software and
the  Bioconductor  packages  limma  and  Agi4x44PreProcess.  Differential  gene
expression was analyzed between TMZ resistant and sensitive cell lines and radiation
resistant  and sensitive cell  lines.  The obtained fold  changes  were analyzed  using
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gene  set  enrichment  analysis  (GSEA)  to  determine  deregulated  pathways  in  the
Reactome database.
Figure 27: Gene expression microarray analysis
A. Volcano plots depicting gene expression fold-changes (log2 scale, x-axis) and p-
values (-log10-transformed, y-axis) of all genes in the data set. Left: Comparison of
radiation resistant  and sensitive cell  lines.  Right:  cell  lines  expressing  the MGMT
gene (TMZ resistant)  and not  expressing  the MGMT gene (TMZ sensitive).  Gene
symbols  are  shown  for  significantly  differentially  expressed  genes  (FDR  <  0.1).  
B. Top ten statistically significant pathways (ranked according to FDR value) after
gene set  enrichment analysis  (GSEA).  NES: normalized enrichment score. Positive
scores indicate up-regulated pathways while negative scores reflect down-regulated
pathways in the dataset. Left: comparison of radiation resistant and sensitive cell
lines. Right: cell lines expressing the MGMT gene (TMZ resistant) and not expressing
the MGMT gene (TMZ sensitive). 
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Volcano  plots  showing  the  genes  with  the  highest  differential  expression  are
depicted  in  Figure  26,  top  panel  (A).  Among  the  cell  lines  showing  different
sensitivity to radiation the ADAMTS4 gene was significantly down-regulated. Other
significantly down-regulated genes were TENM1 and KCNJ10. Furthermore, genes
that  were  strongly  up-regulated  in  radiation  resistant  cell  lines  were  identified
including LRCOL1, OLFM1, KCNK1, TBX1, SULT1A2 and FAM127C. For cell lines with
different  sensitivity  to  TMZ  treatment,  the  genes  CABYR  and  TMEM171  were
considerably  deregulated.  GSEA  revealed  up-regulated  pathways  in  cell  lines
showing  difference  in  radiation  sensitivity  (Figure  26,  mid  panel,  left)  that  were
mainly involved in G1 phase,  RNA polymerase III  transcription initiation and RNA
polymerase III chain elongation. Among the down-regulated pathways, angiopoietin
receptor,  insulin  and  olfactory  transduction  were  identified.  Furthermore,
deregulated pathways between cells showing differences in MGMT expression were
unveiled  (Figure  27,  mid  panel,  right).  Notably,  up-regulated  pathways  were
primarily involved in cell cycle and DNA replication. In contrary, the down-regulated
pathways  were  involved  in  autophagy,  GPCR  downstream  signaling,  olfactory
transduction and signaling and WNT signaling pathway. 
C.1.5 Karyotypic and molecular features of the cell lines allow 
classification into GBM specific subtypes
Studies  from  the  TCGA  consortium  revealed  a  classification  in  GBM  based  on
different molecular features. The subtypes are classified in classical, mesenchymal
and  proneural  mainly  based  on  the  expression  of  EGFR  (classical),  NF1
(mesenchymal)  and  PDGFRA  (proneural).  Patients  belonging  to  the  classical  and
mesenchymal subtypes showed a reduction in overall survival while this observation
was  absent  in  the  proneural  subtype.  In  the  present  study,  the  cell  lines  were
classified according to the patient derived subtypes using gene expression data and
cytogenetic array CGH data. For this purpose, deregulation of major driver genes as
well  as  chromosomal  deletions  and  amplifications  were  scored  based  on  their
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occurrence in the cell lines. For amplifications and deletions in specific genes, the
genomic  location  of  the  genes  was  retrieved  from  the  NCBI  genome  browser
(https://www.ncbi.nlm.nih.gov/genome). In the regions table derived from the aCGH
experiments, the correlating regions were analyzed whether an amplification (+1), a
deletion (-1 or -2), or no change (0) was present in the gene. As depicted in Table 10,
features  present  in  the cell  lines  were scored as  ‘1’  while  absent  features  were
scored as ‘0’. The sum of all features of a subtype was used to build a consensus
score for every cell line and subtype. As shown in Table 10, the majority of the cell
lines (A172, LN18, T98G, U87 and U138) were assigned to the mesenchymal subtype.
The remaining cell  lines LN229 and U251 were classified as classical subtype. The
proneural subtype could not be identified in the cell line panel.
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Table 10: Overview of GBM subtype specific chromosomal amplifications and 
deletions and subtype specific expression of relevant driver genes.
Subtyp
e
Feature A172
LN1
8
LN22
9
T98G U87 U138 U251
C
la
s
s
ic
a
l
Chr. 7 amplification
and Chr. 10 loss
0 1 1 1 1 1 1
EGFR amplification 1 1 1 0 0 0 1
Focal 9p21.3 deletion 1 1 1 1 1 1 1
NES expression 1 0 1 0 0 0 1
NOTCH3 expression 1 0 0 0 1 0 0
SMO expression 1 0 1 1 0 0 1
Score classical 0.83 0.5 0.83 0.5 0.5 0.33 0.83
M
e
se
n
c
h
y
m
a
l Hemizygous deletion
at 17q11.2 (NF1)
1 0 0 0 0 0 0
CHI3L1 expression 1 1 1 1 1 1 1
TRADD, RELB,
TNFRSF1A
expression
1 1 1 1 1 1 1
Score mesenchymal 1 0.67 0.67 0.67 0.67 0.67 0.67
P
ro
n
e
u
ra
l
Focal 4q12
amplification
(PDGFRA)
0 0 0 0 0 0 1
NKX2-2, OLIG2
expression
0 0 0 0 0 0 0
SOX genes
expression
1 0 1 0 0 0 1
Score proneural 0.333 0 0.333 0 0 0 0.67
Consensus M M C M M M C
For each subtype based on cytogenetic alterations and aberrant gene expression, a
score was built. The highest score determined the cytogenetic molecular subtype. 
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C.2 Modulation of miRNA expression by siRNA transfection reveals 
potential targets of the 4-miRNA signature
After characterization of the cell line panel, the expression of the four miRNAs let-7a-
5p,  let-7b-5p,  miR-125a-5p  and  miR-615-5p  was  modulated  by  small  RNA
transfection.  The  cells  were  transfected  using  specific  miRNA  mimics  for
overexpression and miRNA inhibitors for knockdown of the respective miRNAs. In a
first step, the transfection efficiency of the cell  lines A172, LN18,  U87, U138 and
U251  was  analyzed.  The  cell  lines  LN229  and  T98G  were  excluded  from  the
experiment because of their karyotypic complexity. The transfection efficiency was
assessed by FACS using fluorescent-labeled siRNA with concentrations of 10, 5, 1 and
0.5 nM (Figure 28).
The highest transfection efficiency was observed for the cell  lines A172, U87 and
U251 using 10 nM siRNA. The efficiency for these cell lines remained high at 5 nM
siRNA but declined at lower concentrations. The cell lines LN18 and U138 showed
considerably lower efficiency at all siRNA concentrations. 
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Figure 28: Results of the transfection of GBM cell lines using different
siRNA concentration
The cell lines were transfected using RNAiMAX using different concentrations of the
siRNA. The Y-axis shows the transfection efficiency as fraction of the living cells. The
different transfection concentrations are depicted on the X-axis. Cells treated with
transfection reagent alone and untreated cells were used as a control. The colors
represent  the  transfected  cell  lines  U138  (blue),  U87  (red),  A172  (green),  U138
(purple) and LN18 (teal).
For further experiments,  two cell  lines (A172 and U138) were selected.  Selection
criteria  were  transfection  efficiency,  low  karyotypic  complexity  and,  if  possible,
absence  of  subclones.  Additionally,  different  responses  to  radiation  and  TMZ
treatments  were  considered.  The  levels  of  overexpression  and  knockdown,
respectively,  were  characterized  over  a  time  period  of  72  hours  for  the
determination of the optimal concentration and time point of the siRNA transfection
experiment. The cell lines A172 and U138 were transfected using 10 and 5 nM of let-
7a-5p, let-7b-5p, miR-125a-5p and miR-615-5p mimic and inhibitor. The cells were
harvested after 24, 48 and 72 hours. As controls, a siRNA that is not targeting any
miRNA (‘scramble’),  a  transfection control  (‘RNAiMAX’)  and untreated  cells  were
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utilized. The resulting expression changes were normalized to the scramble control.
The  observed  overexpression  in  both  cell  lines  was  highest  after  24  hours  and
decayed over the following 48 and 72 hours (Figure 29, A and B, top panels). The
highest  overexpression  generated  by  10  nM  mimic  RNA  reached  expression
differences of 80-800 times. For the knock down, the highest effect was observed
using 10 nM inhibitor after 24 hours (Figure 29, A and B, bottom panels). The effect
of the knock down weakened during the following 48 and 72 hours. In both cell lines,
the strongest effect could be observed for the miR-125a-5p knock down. Notably, no
effect of the knock down could be observed for miR-615-5p.
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Figure  29:  Results  of  the transfection of  A172 and U138 cells  using
miRNA Mimics and Inhibitors
Transfection of the A172 cell line (A) and the U138 cell line (B). The cell lines were
transfected using miRNA mimics (top panel) and miRNA inhibitors (bottom panel).
The cells were transfected using 5 or 10 nM of the siRNA and the miRNA expression
was analyzed every  24 hours  for  72 hours  by  qRT-PCR.  The resulting expression
changes are shown on the Y-axis. The different transfection conditions are shown on
the X-axis. For normalization of the expressions, a negative transfection control was
utilized (‘scramble’). Additionally, the cells were treated with the reaction reagent
alone (‘RNAiMAX’)  or  were untreated.  The resulting relative overexpressions  are
depicted in the numbers above the bars. 
To characterize the effect on the transcriptome after miRNA inhibitor  and mimic
transfection, 3’-RNA sequencing was performed. Total RNA was isolated from A172
and U138-MG cells, 48 hours after transfection. The cells were transfected using 5
nM  of  the  respective  inhibitor  or  mimic  and  ‘scramble’  inhibitor  or  mimic  was
utilized as control. To analyze differentially expressed genes, the expression of the
respective mimic and inhibitor transfections were compared to the expression in the
‘scramble’ controls. The top five up- and down-regulated genes with a FDR of less
than 0.05 are depicted in Table 11 (A172) and Table 12 (U138-MG). A strong effect of
differential  gene  expression  was  observed  in  A172  cells.  The  resulting  log2  fold
changes were in a magnitude of -40 to 50. Notably, four genes were discovered that
had exactly opposing expressions in response to the let-7a-5p inhibitor and mimic
transfection (HS3ST2, FAM3B, PCP4 and KCNF1; bold letters in the table), suggesting
potential targets of the miRNA. Such clear effects were absent for the other miRNA
transfections. Additionally, FAM3B, PCP4 and KCNF1 were highly up-regulated in the
presence of let-7b-5p, miR-125a-5p and miR-615-5p mimic.
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Table 11: Overview of deregulated genes in A172 cells after miRNA inhibitor and 
mimic transfection
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 Inhibitor Mimic
Gene log2 FC FDR Gene log2 FC FDR
hs
a-
le
t-
7a
-5
p
HS3ST2 23.67 1.02976E-05 FAM3B 50.44 3.67309E-61
PTPRZ1 22.70 6.30014E-06 PCP4 42.22 1.01461E-27
PNLIPRP3 20.23 0.011105951 KCNF1 40.54 3.30229E-31
FOXI1 19.16 2.68066E-06 MAGEA4 24.13 8.77352E-10
PTCHD1 19.00 3.69675E-07 SLC24A3 22.29 3.42141E-10
MMEL1 -16.71 0.002470225 HS3ST2 -22.50 4.53227E-05
TMPRSS4 -17.05 1.963E-06 MIA -23.20 5.27223E-05
FAM3B -17.70 4.45545E-06 LIN28A -28.91 8.63046E-05
PCP4 -18.20 0.000177231 NCCRP1 -34.52 5.31621E-17
KCNF1 -20.74 1.99546E-07 XAGE2 -39.48 9.43261E-09
hs
a-
le
t-
7b
-5
p
CYP4X1 21.14 1.24213E-13 FAM3B 43.31 1.37642E-40
PTPRZ1 21.00 0.000188777 PCP4 41.92 1.79778E-27
PNLIPRP3 19.91 0.026040934 KCNF1 39.81 1.49592E-29
FOXI1 16.14 0.002535677 TRIL 20.94 1.65834E-10
PTCHD1 16.07 0.000729993 SLC24A3 20.45 2.12513E-08
ANKRD1 -7.82 0.013896829 GFRA1 -20.00 0.209321165
CD74 -7.86 0.04824074 APCDD1L -20.08 4.45778E-19
LPAR1 -21.09 9.80792E-21 IL1B -22.65 4.84278E-11
C5orf66-AS1 -22.48 4.01166E-12 LIN28A -29.67 4.36989E-05
ADA2 -28.25 0.018743528 NDN -47.48 3.77155E-59
hs
a-
m
iR
-1
25
a-
5p
FOXI1 22.65 9.69022E-10 FAM3B 43.75 3.19347E-42
PTCHD1 18.97 1.94217E-07 PCP4 40.90 2.55002E-25
CYP4X1 18.55 7.46548E-10 KCNF1 40.52 1.63986E-31
HS3ST2 18.00 0.016203286 MAGEA4 22.16 5.1308E-08
APOD 8.51 0.025681717 TRIL 17.17 4.53257E-06
PDE2A -6.65 0.03338845 ABCC11 -19.18 3.11705E-05
ANKRD1 -8.12 0.004693111 SCNN1G -21.10 0.00064104
NFE4 -17.36 3.30407E-06 SHC3 -22.00 5.01429E-10
APCDD1L -22.52 2.6487E-24 NCCRP1 -35.08 1.29984E-17
SPX -36.52 2.81321E-26 XAGE2 -40.14 5.42512E-09
hs
a-
m
iR
-6
15
-5
p
HS3ST2 23.43 1.3771E-05 FAM3B 44.05 4.83098E-44
PNLIPRP3 23.11 0.000799727 PCP4 42.03 6.4233E-28
CYP4X1 20.43 7.75756E-13 KCNF1 40.00 3.27525E-30
PTPRZ1 19.47 0.000445397 SLC24A3 20.75 1.30115E-08
PTCHD1 16.47 8.84034E-05 TRIL 20.52 6.49767E-10
FBLN2 -21.26 1.13711E-05 ABCC11 -19.52 2.79656E-05
ADA2 -28.52 0.007707694 TCN1 -21.42 1.50849E-21
NCCRP1 -34.11 1.93466E-16 SCNN1G -21.51 0.000624453
SPX -35.07 2.68692E-24 VAV1 -43.16 2.9684E-60
LINC02434 -42.34 1.68097E-28 MMEL1 -43.19 6.39914E-28
Results
Table 12: Overview of deregulated genes in U138-MG cells after miRNA inhibitor 
and mimic transfection
log2 FC: log2 fold change 
FDR: false discovery rate
bold: genes that showed 
exactly opposing 
expressions between 
mimic and inhibitor 
transfections
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Mimic
 Gene log2 FC FDR
hs
a-
le
t-
7a
-5
p
PRRG4 4.09 0.006968769
PTPMT1 2.05 0.002917628
HMOX1 2.03 0.009821705
MET 1.78 4.46838E-08
DPYSL3 1.51 2.78876E-06
CPA4 -1.85 3.18271E-06
MIER2 -1.92 0.001180775
DICER1 -2.15 8.80187E-13
PLAGL2 -2.29 0.000979854
POU2F2 -2.35 4.30648E-07
hs
a-
le
t-
7b
-5
p
KRT34 2.73 0.008894405
HMOX1 2.13 0.006116614
PTPMT1 2.09 0.002719916
MET 1.94 9.28833E-10
DPYSL3 1.29 0.000270753
C18orf21 -2.26 0.012885386
FKRP -2.50 0.03711204
LOXL3 -2.75 0.047404822
E2F5 -2.88 0.012343437
ACVR2B -3.63 0.030468319
hs
a-
m
iR
-1
25
a-
5p
MET 1.69 7.49606E-07
DPYSL3 1.11 0.007375316
PDCD6 1.09 0.001860794
ANKRD52 0.98 0.023475619
MCFD2 0.83 5.91564E-05
EIF4EBP2 0.28 4.03283E-10
ATOH8 0.58 0.013411369
MTFP1 0.64 0.028642189
KRTAP2-3 -6.14 0.044397781
ENTPD1-AS1 -6.53 0.004303527
hs
a-
m
iR
-6
15
-5
p
MET 1.51 5.90483E-05
PDIA4 1.25 0.042458523
ELOA 1.19 0.039372919
DPYSL3 1.15 0.006201529
PDCD6 1.01 0.006201529
SBNO1 0.69 0.006201529
MAP3K20 0.63 0.032217076
MCFD2 0.62 0.023989317
TRMT112 0.59 0.004444782
MICAL2 -0.74 0.001619159
Results
In the U138-MG inhibitor transfection experiment, no differentially expressed genes
could be found. Additionally, the effect of the mimic transfection was much smaller
than in A172 cells. Notably,  the genes MET and DPYSL3 were up-regulated in the
presence of each miRNA mimic.
C.3 Knockout of miRNAs using CRISPR/Cas9
After transient knockdown and overexpression was established, the miRNAs let-7a-
5p,  let-7b-5p and miR-125a-5p were knocked out  using the CRISPR/Cas9  system.
Therefore, plasmids had to be transfected expressing Cas9 and the miRNA specific
guide RNAs. Afterwards, knockouts were identified using a T7 endonuclease assay.
To characterize the knockouts, single clones had to be generated. The cell lines were
selected as described in C.2. Additionally, for the purpose of knocking out all alleles,
low karyotypic complexity was required. In a first step, guide RNAs were designed
targeting the miRNA precursor sequence. Those guide RNAs were received as oligos
with 5’- and 3’-overlaps homologous to the upstream and downstream regions of
the donor plasmid. For each guide RNA, forward and reverse oligos were annealed
and cloned into the MLM3636 plasmid using Gibson cloning. The amount of oligo
and plasmid was either in equimolar amounts (1:1) or in excess of the oligo (1:5).
After  transformation  in  bacteria,  six  colonies  were  picked  and  the  plasmid  was
purified from the bacteria. For validation of the plasmids, PCR was performed that
utilized  the  introduced  guide  sequence  for  binding  of  the  reverse  primer.  Thus,
creation of a PCR product was only possible if the guide RNA was correctly inserted.
The PCR products were visualized using agarose gel electrophoresis (Figure 30).
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Figure 30: Agarose gel image visualizing the PCR products of the 
MLM3636 plasmid with guide RNAs
The plasmids were generated using Gibson cloning in equal amounts of insert and
backbone  (1:1)  or  in  excess  of  the  backbone  (1:5).  After  transformation  in
competent bacteria, six colonies were picked and tested via PCR. The arrows are
reflecting successful insert of the guide RNA. 
Afterwards, the transfection efficiency of the cell lines U87-MG and U138-MG using
plasmids  was  analyzed.  Therefore,  a  GFP  plasmid  was  transfected  with  different
amounts of lipofectamine (Figure 31). The cells were harvested after 24 hours and
GFP  positive  cells  were  analyzed  using  FACS.  As  shown  in  Figure  31,  different
lipofectamine amounts exhibited only minimal effects on the transfection efficiency.
U138-MG cells showed a higher transfection rate (25%) than U87-MG cells (17%).
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Figure 31: Results of the transfection of the plasmid pFG4-GFP
U87 and U138 were transfected with the plasmid pFG4-GFP using Lipofectamine
3000.  The  transfection  efficiency  is  displayed  on  the  Y-axis  as  a  fraction  of  the
amount of living cells. The different transfections are displayed on the X-axis. The
cells  were treated  using  different  amounts  (3.75  and 7.5  µl)  of  the transfection
reagent (‘Lipofectamine’). Additionally, as controls the cells were treated with the
transfection reagent or the GFP plasmid alone. 
To analyze whether knockouts after transfection of the CRISPR plasmids occurred, a
T7 endonuclease assay was performed. Therefore, the plasmids carrying the guide
RNAs were co-transfected with the Cas9 expressing plasmid VP12. Afterwards, the
transfected cell pool was harvested and genomic DNA was purified from the cells.
PCR analysis using primers that amplify the desired knockout site was performed.
The  PCR products  were denatured and slowly re-annealed.  In  case  of  successful
knockouts, heterodimers were formed that carry mismatches between the knockout
and the wild type PCR fragments. T7 endonuclease cleaved the mismatched dimers
and the resulting fragments  were analyzed  using agarose  gel  electrophoresis.  As
shown in Figure 32, only one visible band could be identified, meaning the CRISPR
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knockout  was  not  successful.  After  re-evaluation  of  the  CRISPR  system  multiple
challenges were identified. A major concern was that a knockout of the mature 5’-
miRNA  sequence  also  affects  the  expression  of  the  complementary  mature  3’-
miRNA. A detailed discussion of miRNA knockout using CRISPR/Cas9 follows in the
Discussion section.
Let-7a Let-7b
miR-125a
Figure  32: T7-endonuclease assay shows no effect of the transfected
CRISPR-Cas9 system
U87-MG  cells  were  transfected  with  the  Cas9  plasmid  (VP12)  and  a  guide  RNA
expression  plasmid  targeting  let-7a-5p,  let-7b-5p  or  miR-125a-5p.  The  intended
knockout positions were analyzed using the T7-endonuclease assay. Only one band
is visible on the gel meaning the knockout did not succeed.
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D Discussion
The aim of this thesis was to validate a prognostic 4-miRNA signature in GBM and to
uncover  the  functional  role  of  the  miRNAs.  The  4-miRNA  signature  was  first
discovered  as  a  prognostic  classifier  by  Niyazi  et  al.,  (2016) and  allows  the
classification of GBM patients into high and low-risk groups that could be further
sub-stratified into four risk groups by inclusion of the MGMT promoter methylation
status. Generally, survival of GBM patients is poor due to the diffuse and infiltrative
nature of the tumor and the appearance of treatment resistant clones after initial
therapy (Delgado-López and Corrales-García, 2016). Thereby, there is medical need
for  an  improvement  and  optimization  of  the  standard-of-care  therapy,  which
requires a stratification of GBM patients. Usually, miRNAs control a variety of genes
and a functional characterization is needed for the determination of their biological
role. Therefore, it is important to characterize the functional role of the four miRNAs
of  the signature  in  an in  vitro cell  culture  model.  For  this  example  of  a  reverse
translation from a patient derived observation into a cell culture a careful analysis of
the model system is required in order to simulate actual tumor phenotypes. Seven
established cell lines were thoroughly characterized. Special emphasis was put on
the  authentication  of  the  cell  lines  and  GBM-specific  cytogenetic  alterations.
Furthermore, the cytogenetic complexity and the presence of cytogenetic subclones
was analyzed. Also, the response to GBM standard-of-care treatment, which includes
radiation response and TMZ sensitivity,  was characterized. Additionally,  molecular
features  of  the  cell  lines  were  analyzed  to  assign  the  cell  lines  to  GBM specific
subtypes and to assort the GBM cell lines into patient-derived risk groups.
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D.1 Cell line authentication and cytogenetic characterization
Cell lines models are a challenge in terms of cross-contamination, clonal evolution in
vitro or confusion of samples during experiments. Therefore, scientific journals have
started asking for obligatory cell line authentication data  (Fusenig et al., 2017) and
are  establishing  global  quality  measures.  Thus,  authentication  and  avoidance  of
confusion of cells lines is a prerequisite for their usage as model systems. Recently, it
was  shown that  one  of  the most  common GBM cell  line  U87-MG might  not  be
authentic to the supposed tumor origin (Allen et al., 2016). The authors showed that
the STR-profile of the commercially available U87-MG is not matching the STR-profile
of the original cell line established in the 1960s. However, the authors also analyzed
the mRNA expression profile and showed that the cell  line is most likely of GBM
origin.  Despite this  GBM-like phenotype,  the usage of  this  cell  line for  preclinical
GBM research remains questionable due to an overall uncertainty about its origin.
This  example  demonstrates  the  importance  to  verify  of  cell  lines  by  STR-typing.
Except  for  U87-MG,  all  characterized  markers  were  matching  to  the  respective
database  (www.dsmz.de)  entries.  In  addition  to  STR-profiling,  information  was
needed  about  the  ploidy  and  genetic  heterogeneity  of  all  cell  lines.  Therefore,
spectral karyotyping (SKY) was performed to investigate ploidy, subclones and clonal
evolution.  SKY  analysis  unveiled  a  high  cytogentic  variance  and  the  presence  of
subclones in five out of seven cell lines. Four cell lines (LN18, U87-MG, U138-MG and
U251-MG) showed a near-diploid or near-triploid karyotype, while three cell  lines
(A172, LN229 and T98G) exhibited a near-tetraploid or near-hexaploid karyotype. In
GBM, karyotypic complexity is a common observation. Dahlback et al. (2009) showed
that  cell  lines  established  from  patient  derived  tumors  usually  exhibit  abnormal
karyotypes  and a  high  cytogenetic complexity.  Another  study  by  Magnani  et  al.,
(1994) showed  that  GBM  cells  usually  harbor  near-diplod  and  near-triploid
karyotypes. The most common cytogenetic marker of GBM is loss of heterozygosity
on chromosome 10 (Thakkar et al., 2014). These alterations can either consist of the
loss of a whole chromosome or parts of the short or long arm of the chromosome
(Ohgaki and Kleihues, 2007). 
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In the cell line panel, only U87-MG showed loss of heterozygosity on chromosome 10
while the other cell lines either showed an amplification of chromosome 10 (A172,
LN18, LN229 and T98G) or no alteration of chromosome 10 at all  (U138-MG and
U251-MG).  Intra-tumor  heterogeneity  in  the  form  of  subclones  is  a  common
observation  in  GBM  (Dahlback  et  al.,  2009).  Among  the  cell  lines  of  the  panel,
subclones were identified in almost all cell lines, except for U138-MG and U251-MG.
This observation might be in particular relevant for their usage in preclinical studies
dealing  with  clonal  approaches  in  order  to  determine  radiotherapeutic  and/or
chemotherapeutic effects. 
D.2 Radiation and TMZ sensitivity of the GBM cell lines
For therapeutic success, the response of tumor cells to specific treatments is crucial.
Clonogenic  survival  assays  are  considered  as  “gold  standard”  to  determine  the
treatment response to irradiation and chemotherapeutic treatment  (Mirzayans et
al.,  2007) and were first described in 1956  (Puck and Marcus, 1956). The assay is
primarily  used  for  analyzing  the  colony  formation  ability  of  single  cells  and  the
survival  fraction is  a  measure  of  radiation  resistance.  In  our  data  no correlation
between the ploidy and the resistance of the cells to radiation treatment could be
observed in the cell line panel. The cell line with the lowest ploidy U87-MG (near-
diploid)  was  the  most  resistant  cell  line,  while  LN229  cells  harboring  a  near-
tetraploid karyotype was the most sensitive cell line. Earlier studies have shown that
the amount of lethal chromosomal damage increases with ploidy  (Schwartz et al.,
1999). However, the authors indicate that the survival of cells is also determined by
other factors such as DNA damage response and subsequent DNA repair efficiency. 
Differences  in  the  survival  between  cells  after  a  specific  treatment  are  usually
analyzed  using  a  linear  quadratic  model  that  describes  survival  as  a  function of
treatment response (Barendsen, 1982). The model divides the survival curves into a
linear part (α value) and a quadratic part (β value). The α value is generally used to
describe the survival at low doses and the β value represents the effectiveness of the
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treatment at higher doses  (Barendsen, 1982). The α/β ratio describes the dose at
which the linear and quadratic part of the curve contribute equally to the survival of
the cells (Franken et al., 2013). The linear term of this model is supposed to describe
lethal  DNA  damage  in  the  form of  double  strand  breaks  originating  from single
irradiation hits, while the quadratic term describes lethal double strand breaks from
multiple independent irradiation hits  (Unkel et al.,  2016). For clinical applications,
this approach supports the selection of optimal fractionation schedules in radiation
oncology, by optimizing the dose per fraction, dose fractionation and dose rate in
relation to  tissue-specific  α/β ratios  (Franken et  al.,  2013).  The  α/β ratio is  also
utilized to describe radiosensitizing effects of treatments where an increase in the α/
β  ratio  reflects  higher  sensitivity  towards  irradiation  while  a  lower  α/β  ratio
describes higher resistance to irradiation (Franken et al., 2013). There are scenarios
for which the α/β ratio inadequately describes differences in radiation response. This
could  be  the  case  if  curves  with  a  similar  α/β  ratio  have  a  different  steepness.
Therefore,  alternative  approaches  were  suggested  to  determine  the  cellular
response towards ionizing radiation. Principal component analysis may be used to
describe radiosensitivity between cell  lines of a specific data set. As described by
Unkel et al., (2016), the first principal component of the analyzed surviving fractions
represents  a  measure  of  the  clonogenic  survival  over  the  whole  dose  range.
Therefore,  the  authors  suggest  utilizing  principal  component  scores  for  the
description of the cellular response towards irradiation.
In this thesis, linear quadratic model dose-response curves were established for each
GBM cell line to analyze differences in the sensitivity of the cell lines to radiation
treatment. Statistical analysis of the survival curves using a F-test was carried out as
described in Braselmann et al., (2015). In the dose range of 1-10 Gy T98G and U87-
MG cells showed the most resistant radiation response while LN229 cells were most
sensitive. In collaboration with Nikko Brix and Leon Schnöller from the Department
of Radiotherapy and Radiation Oncology at the LMU University Hospital Munich, the
survival  data  after  irradiation  treatment  were  independently  repeated  using  the
same GBM cell line panel for a dose range of 1-6 Gy. The resulting survival data was
evaluated using a principal component analysis as described by Unkel et al., (2016). 
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To  classify  the  cell  lines  into  resistant  and  sensitive  groups,  reduction  of  data
complexity of the survival data was done by cluster analysis and principal component
analysis. For this purpose, survival data at each dose were linearly transformed into
uncorrelated variables. Afterwards, the first principal component score was used for
the  determination  of  a  radioresistance  score.  Classification  of  the  cell  lines  into
different radiation sensitivity groups was determined by combined consideration of
the linear quadratic survival curves and the principal component scores. Due to the
above-mentioned data transformation, the resulting principal component scores are
only valid for a defined set of cell lines and scores might change if additional cell lines
are  added to  the  data  set.  Additionally,  the  correlation  of  an  individual  survival
fraction to a specific dose is abolished. Nevertheless, this approach provided the best
resolution  of  individual  differences  of  radiation  sensitivity  between  cell  lines.
Principal component analysis classified the cell lines T98G, U87-MG U251-MG and
A172 as more resistant whereas U138-MG, LN18 and LN229 were more sensitive.
Three groups became apparent that showed significant differences in the survival
curves. The cell lines T98G and U87-MG showed the highest resistance to radiation
while  A172,  LN18,  U138-MG  and  U251-MG  showed  intermediate  resistance  and
LN229 was most sensitive according to F-test analysis as described above. The cell
lines  with the most  extreme response to irradiation (T98G,  U87-MG and LN229)
showed comparable results in both analyses while cell lines with a smaller difference
in their response to irradiation exhibited varying results (A172, LN18, U138-MG and
U251-MG).  This  indicates  similar  results  with both approaches  for  cell  lines  with
extreme radiation responses but distinct differences for cell lines with more similar
responses to irradiation.
Accordingly, the colony formation assay was performed to determine the response
of each cell line towards TMZ treatment. In comparison to a single dose irradiation
treatment,  the cells  were incubated in the presence of  TMZ for  24 hours.  LN18,
T98G, U138-MG and U251-MG cells were highly resistant to TMZ while A172, LN229
and U87-MG were sensitive to TMZ. In this context the expression and the promoter
methylation status of the MGMT gene is important. MGMT removes the effect of
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TMZ thus making cells resistant to the treatment (Brandes et al., 2008). Two of the
most resistant cell lines (LN18 and U138-MG) showed no methylation of the MGMT
promoter and no expression of the MGMT gene while the three most sensitive cell
lines (A172, LN229 and U87-MG) were methylated. It is interesting to note that two
of  the  more  resistant  cell  lines  (T98G  and  U251-MG)  showed  expression  of  the
MGMT gene, however at low levels. Therefore, it can be concluded from these data
that resistance to TMZ was better reflected by the MGMT gene expression than by
MGMT promoter  methylation  status.  The expression  level  of  the MGMT gene  is
obviously of crucial  impact. An explanation for this observation of a differentially
expressed MGMT gene might be due to the differing ploidy of the cell lines, which
generates  a  distinct  heterogeneity  for  MGMT  expression  because  a  loss  of  the
MGMT  promoter  methylation  on  some  loci  or  genetic  subclones  modulate  the
expression of the gene. 
D.3 Molecular subtypes of the GBM cell lines
A correlation analysis of gene expression patterns with clinical outcome is a common
approach  to  define  subgroups  of  patients  and  to  achieve  a  stratification  into
different  risk  groups.  As  exemplified  for  breast  cancer,  the  expression  of  the
estrogen  receptor  and  human  epidermal  growth  factor  receptor  2  could  be
associated with a more favorable clinical outcome because a targeted therapy for
these two genes is here effective. On the other hand, tumors lacking the expression
of both genes displayed a poorer prognosis (Desmedt et al., 2008). Another example
in  prostate  cancer  was  the  expression  of  MUC1  and  AZGP1  which  were  highly
predictive  for  tumor  recurrence  independent  of  tumor  grade,  stage,  and
preoperative  prostate-specific  antigen  levels  (Lapointe  et  al.,  2004).  Such
observations render the question about different molecular subtypes in cancer. In
GBM, four  molecular  subtypes  were  described using  gene expression  microarray
data from the TCGA database: classical, mesenchymal, proneural and neural subtype
(Verhaak et al., 2010). In a subsequent study the neural subtype was interpreted as
not tumor specific because it could be associated with normal tissue (Wang et al.,
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2017). The different subtypes were identified in a set of 200 GBM samples on three
different microarray platforms. Clustering analysis of 1720 genes with the highest
overall variance revealed four clusters with differential gene expression (Verhaak et
al., 2010). Out of this larger gene set, 210 signature genes were identified for each
subtype  (Verhaak  et  al.,  2010).  Additionally,  the  expression  of  previously  known
GBM driver genes was analyzed in the subtypes (Verhaak et al., 2010). The subtypes
differed in their  clinical  prognosis  with the proneural  subtype showing the worst
survival  (Verhaak  et  al.,  2010).  These  subtypes  may  be  utilized  for  targeting  of
subtype specific pathways and identification of personalized treatment options for
GBM patients.
For this reason, the cell lines of this thesis were classified into classical, mesenchymal
and proneural subtypes based on GBM-specific driver gene expressions. The most
characteristic  genes  of  the  subgroups  were  EGFR  amplification  in  the  classical
subgroup, NF1 deletion in the mesenchymal subgroup and PDGFRA amplification in
the proneural subgroup. Cytogenetic features of the cell lines were combined with
mRNA expression data  to generate  a scoring for  each cell  line.  In  this  thesis  the
presence or absence of characteristic alterations were analyzed in order to calculate
consensus scores for the classification of the cell lines into the molecular subtypes
(Table 10, Results). According to this subtype classification, the majority of the cell
lines were mesenchymal (A172, LN18, U87-MG, T98G and U138-MG) while the cell
lines U251-MG and LN229 were classical. Molecular subtyping in established GBM
cell lines is sparsely investigated.  Xie et al., (2015) characterized a 48 GBM cell line
panel  that  was created from GBM tumor samples.  The authors  showed that  the
majority  of  the cell  lines  resemble  the mesenchymal  subtype while  classical  and
proneural subtypes occurred less frequently. Overall, the distribution of the subtypes
described  in  this  thesis  reflected  the  observation  by  Verhaak  et  al.,  (2010),
suggesting  that  cultured  GBM  cell  lines  belong  primarily  to  the  mesenchymal
subtype.
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D.4 Validation and assignment of cell lines to patient risk groups
To  establish  personalized  treatment  options  for  cancer  patients,  prognostic
molecular  markers  are  emerging  that  may  be  utilized  in  combination  with  new
technologies like improved imaging and particle therapy (Baumann et al., 2016). For
this  purpose,  stratification  of  patients  into  risk  groups  is  a  prerequisite  for  the
identification of molecular  markers.  Such molecular classifiers consist of  aberrant
expression of genes and miRNAs that is correlated with clinical parameters in order
to allow a prediction of the treatment response. 
Recently,  a prognostic 4-miRNA signature was described  (Niyazi  et al.,  2016) that
enabled a classification of standard-of-care treated GBM patients into low- and high-
risk groups. The signature was identified in a retrospective set of 36 GBM patients. A
forward selection approach was utilized for identification of significantly expressed
miRNAs that had the largest impact on the survival of the patients. The resulting
miRNA signature was the basis for a stratification into low- and high-risk groups.
Patients  belonging  to  the  low-risk  group  showed  an  increased  survival  after
standard-of-care  treatment  in  comparison  to  patients  belonging  to  the  high-risk
group. Additionally,  the signature was independently validated in a subset of the
TCGA GBM database  using  qRT-PCR.  In  a  following  study  by  Unger  et  al.,  (2020
submitted) the prognostic value of the miRNA signature was validated in a 106 GBM
patient  cohort  from  the  LMU  Munich  (n=37),  the  University  Hospital  Düsseldorf
(n=33) and The Cancer Genome Atlas (n=36). The tumors were all IDH1/2 wildtype
with known MGMT promoter methylations. Overall survival (OS) of the patients was
analyzed for combinations of risk score and MGMT promoter methylation. We could
show that patients with a low-risk signature and methylated MGMT promoter had
superior  OS (median OS:  37,4 months) in comparison to patients with a  low-risk
signature and unmethylated promoter (median OS: 24,8 months). Accordingly, this
could also be shown for patients with a high-risk signature and methylated MGMT
promoter  (median  OS:  18,2  months)  and  patients  with  a  high-risk  signature  and
unmethylated MGMT promoter (median OS: 14,3 months). These data suggest that
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the miRNA signature in combination with the MGMT promoter methylation status
serves as a strong predictor for the clinical outcome of GBM.
To further characterize the risk groups and to create model systems for the different
subgroups, the characterized cell  line panel can be utilized. These model systems
also offer the possibility to find correlations between phenotypical and molecular
characteristics in specific risk groups. In the present thesis, the expression of the 4-
miRNAs was analyzed  in the GBM cell  line  panel  using qRT-PCR to generate  risk
scores for each cell line. Based on the obtained risk score, the cell lines T98G, U87-
MG and U251-MG were classified as low-risk while the cell lines A172, LN18, LN229
and  U138-MG  were  assorted  to  the  high-risk  group.  An  association  with
radioresistance  scores  indicated  a  reverse  correlation  between  risk  score  and
radiation  sensitivity  (T98G  and  U87-MG  were  highly  resistant  to  radiation).
Additionally,  no  correlation could be  observed between the risk  factor  and TMZ
treatment. This is an unexpected finding and might be explained by several reasons.
First  of  all,  different  treatments  in  the patient  cohort  and in  the cell  lines  were
applied.  The  standard-of-care  treatment  for  patients  consists  of  30x  2  Gy
radiotherapy in combination with adjuvant TMZ chemotherapy. The cell lines only
received  a  single  dose  of  radiation  and  TMZ  treatment  was  performed
independently.  Furthermore,  analysis  of  the  let-7  miRNAs  using  qRT-PCR  was
challenging due to technical reasons related to the let7 family members. In humans,
let-7c and let-7f only show one base pair difference in comparison to let-7a and let-
7b (Lee et al., 2016). This suggests that primers amplifying let-7a and let-7b possibly
amplify  other  let-7  miRNAs  as  well.  Therefore,  qRT-PCR measurement might  not
correctly reflect the expression of  the miRNAs let-7a-5p and let-7b-5p in the cell
lines. As a third factor for disagreement, subclones were identified in almost all cell
lines that possibly influences expression of the miRNAs.  Thus,  microarray derived
observations from patients might not be transferrable to expression data generated
by qRT-PCR of in vitro cell culture systems. In GBM patients, a negative contribution
to survival comes from the infiltrative nature of the tumor and the occurrence of
treatment  resistant  cell  clones  shortly  after  initial  therapy  (Delgado-López  and
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Corrales-García,  2016).  Those  effects  are  absent  in  cell  culture  experiments.  In
conclusion, cell line models for specific patient risk groups could not be identified.
D.5 Selection of cell lines for functional studies of the 4-miRNAs
Although risk group specific cell line models are difficult to identify, the cell lines still
allow a mechanistic investigation of the miRNAs of the signature. To characterize
potential targets of the 4-miRNAs, suitable cell lines were selected for a modification
of the 4-miRNA expressions. Based on the previous characterization, the cell lines
A172 and U138-MG were chosen for further experiments. Both cell lines show less
complex karyotypic changes and subclones were absent in the U138-MG cell line.
Additional features of the cell lines were considered for the selection of the A172
and U138 cell line models: MGMT expression, methylation of the MGMT promoter,
radiation response, GBM subtype and transfection efficiency. The remaining cell lines
were not included because of either high ploidy and presence of subclones (LN229,
T98G) or low transfection efficiency (LN18, U251-MG). The latter is of special interest
because  low  amounts  of  transfected  cells  might  not  generate  a  significant
phenotypic effect of the transfection.
D.6 Different approaches for modification of miRNA expression
A complete knockout of the mature miRNA by genome editing tools like the CRISPR/
Cas9  system  is  a  major  challenge  for  an  experimental  modification  of  miRNA
expression.  Stable  knockouts  usually  require  creation  of  plasmids  and  extensive
target screening and validation experiments. Transient transfection using small RNAs
provide  a  more  rapid  transfection  process  but  the  modification  of  the  miRNA
expression is only achieved for a limited time frame. Therefore, an identification of
possible miRNA targets was carried out either by transient overexpression or by a
stable knock down of the miRNAs in the selected cell lines. A transient modification
was  achieved  by  transfection  of  small  RNA  molecules  that  either  have  a  similar
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function as mature miRNAs (mimics) or inhibit endogenous miRNAs (inhibitors). A
major  challenge  for  the  transfection  of  small  RNAs  lies  in  the  possibility  of
introducing  off-target  effects  by  increasing  or  lowering  the  expression  of  other
miRNAs with a high sequence similarity. Target recognition of the miRNA relies only
on a small base pair sequence and high overexpression of the miRNAs and might
lead to unwanted inhibition of  mRNA targets  (Lam et al.,  2015).  Additionally the
external  miRNAs  compete  with  endogenously  expressed  miRNAs  for  regulatory
proteins like RISC and other factors (Lam et al., 2015). Notably, studies have shown
that oversaturation of miRNAs may even cause fatality in mice (Grimm et al., 2006).
In conclusion, modification of miRNA expression by small RNAs provides a powerful
tool for miRNA target identification but have possible off-target effects that might
introduce bias into the data. 
Another possibility to gain new insights into miRNA function is the investigation of
stable,  long-term  knockouts  of  the  miRNAs  using  the  CRISPR/Cas9  system.  The
technology is suitable for a permanent inhibition of the miRNAs. Thereby, long-term
effects  of  the  miRNA  knockout  in  in  vitro  and  in  vivo  assays  can  be  observed.
Surprisingly,  given the novelty  and interest  in CRISPR technology  in the research
community,  only  few  research  papers  describe  miRNA  knockouts  using  CRISPR.
Chang et al., (2016) reported a decrease of the expression of miRNAs by 96% using
CRISPR. The authors constructed guide RNAs to target the stem-loop sequence of
the miRNAs but it was not indicated whether the mature 5p-miRNA was knocked
down or the 3p-miRNA or both. A loss in the complementarity of the miRNA stem-
loop will  inhibit its processing by RISC which will  result in the loss of both active
forms  of  the  miRNA.  Therefore,  observed  effects  in  the  gene  expression  profile
cannot be assigned to any of the mature miRNAs. Furthermore, Chang et al., (2016)
observed that CRISPR-mediated knockout of miR-200c also inhibits the expression of
another miRNA (miR-141). The authors found that repression of miR-200c triggers a
negative  feedback  loop  by  upregulation  of  the  gene  ZEB1  that  inhibits  miR-141
expression. For the miRNAs from the prognostic signature, the miRNAs let-7a, let-7b
and miR-125a are encoded on genomic clusters with other miRNAs. These clustered
miRNAs are expressed on a single transcript  (Lee et al., 2016) and modification of
any of the miRNAs might also inhibit the expression of the others. Another technical
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pitfall exists in working with cells that show high ploidy. For knockout of the miRNAs,
the  majority  of  the  alleles  had  to  be  knocked  out  as  the  expression  might  be
substituted by the miRNA expression of the other alleles. This poses even a further
challenge  for  miRNAs  like  let-7a  that  are  encoded  on  different  positions  of  the
genome with different  pri-miRNA sequences  but  all  expressing  the same mature
miRNA sequence  (Lee et al.,  2016).  Repression of  let-7a expression using CRISPR
would not only require to knockout all alleles but all different pri-miRNA sequences
as well. In conclusion, CRISPR offers a highly potential system for loss-of function
studies targeting genes but for miRNA research certain limitations exist for knockout
of  specific  mature  miRNAs.  Therefore,  in  this  thesis  miRNA  modification  was
ultimately carried out by transient transfection of miRNA mimics and inhibitors.
D.7 Genes regulated by the 4-miRNAs
Global transcriptome measurements like microarrays or mRNA sequencing provide a
powerful tool for analysis of miRNA mediated gene expression. As miRNAs repress
the  expression  of  their  targets,  the  loss  of  miRNA function  by  miRNA inhibitors
should lead to increased target expression (Hausser and Zavolan, 2014). Accordingly,
gain of miRNA function by miRNA mimics should lead to a reduced target expression.
Therefore, genes that show opposing effects after mimic and inhibitor transfection
represent good candidates as potential miRNA targets.
In  this  thesis  3’  RNA-sequencing  was  performed  for  the  identification  of  miRNA
targets. Differentially expressed genes were unveiled in A172 and U138-MG cells by
characterization  of  the  global  gene  expression  using  mRNA sequencing  between
miRNA inhibitor or mimic transfected cells and their respective ‘scramble’ controls.
In the U138-MG cells no differentially expressed genes were found after transfection
with the inhibitor, which is possibly due to technical reasons like a low transfection
efficiency for one of the modulations. Nevertheless, in A172 cells strong effects of
the miRNA inhibitor and mimic transfection could be observed. Thereby, four genes
could be identified that show opposing expression in the presence of the let-7a-5p
inhibitor and mimic: FAM3B, PCP4, KNCF1 and HS3ST2. The genes FAM3B, PCP4 and
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KNCF1 showed strong up-regulation in the presence of the miRNA mimic while the
genes  were  down-regulated  in  the  presence  of  the  inhibitor.  These  genes  are
possibly indirectly regulated by the let-7a-5p miRNA. In contrary, the HS3ST2 gene is
down-regulated in the presence of the mimic and up-regulated in the presence of
the inhibitor suggesting that this gene is supposed to be a direct target of the let-7a-
5p miRNA. 
The functional roles of the identified genes were previously described and all of the
genes  could  be  associated  with  cancer  processes.  Notably,  FAM3B,  KCNF1  and
HS3ST2 have been reported to correlate with tumor invasiveness in colon, lung and
breast  cancer  (Li  et  al.,  2013;  Baskaran,  2017; Kumar  et  al.,  2014).  FAM3B  is  a
secreted cytokine that was first discovered in the Langerhans islets of the pancreas
and is believed to play a role in the process of pancreatic β-cell apoptosis (Cao et al.,
2003). More recently, FAM3B could be associated with increased invasion of colon
cancer cells (Li et al., 2013). PCP4 plays an important role for synaptic function in the
cerebellum  (Wei  et  al.,  2011).  PCP4  knockout  mice  exhibit  impaired  locomotor
learning  (Wei  et  al.,  2011).  Additionally,  it  was  reported  that  PCP4  regulates
apoptosis  in  breast  cancer  (Hamada  et  al.,  2014).  The  gene  KCNF1  is  sparsely
investigated. Recently, KCNF1 was associated with cell proliferation and invasion in
lung cancer, acting as tumor promoter  (Baskaran, 2017). HS3ST2 is associated with
Alzheimer disease and plays a role in the development of the disease-specific tau
subtype  (Sepulveda-Diaz et al.,  2015).  Additionally,  the gene is involved in breast
cancer cell invasion and chemosensitivity  (Kumar et al.,  2014). None of the genes
have  been  associated  with  let-7a  so  far  (http://mirtarbase.mbc.nctu.edu.tw),
suggesting that these genes may be novel targets of the miRNA. Notably,  by this
approach  only  a  fraction of  the  miRNA  targets  can  be  uncovered  as  two  major
pathways for miRNA induced target inhibition exist: miRNA-induced degradation of
the mRNA and inhibition of  translation  (Huntzinger  and Izaurralde,  2011).  Target
inhibition by repression of translation has only influence on protein expression but
has no impact on the abundance of the mRNA (Olsen and Ambros, 1999). Therefore,
those genes will not show differential gene expression using transcriptome analyses. 
As shown in Table 11 no genes with opposing effects could be found for the miRNAs
let-7b-5p,  miR-125a-5p  and  miR-615-5p.  Notably,  the  gene  LIN28A  was  strongly
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down regulated after let-7a-5p and let-7b-5p mimic transfections. LIN28 is a family
of RNA binding proteins (Guo et al., 2006) that negatively regulate the expression of
the let-7 precursor RNAs (Heo et al., 2008). Interestingly, the let-7 miRNAs are itself
negatively  regulating  the  expression  of  LIN28,  thus  creating  a  double  negative
feedback loop (Balzeau et al., 2017). Multiple studies have shown that expression of
LIN28 and loss of let-7 expression leads to poor prognosis in cancer patients (Balzeau
et al., 2017). It could also be shown that the expression of LIN28 was a predictor for
clinical outcome in GBM patients (Qin et al., 2014). In conclusion, these observations
might be an indication why the let-7 miRNAs of the signature were higher expressed
in low-risk group comared to the high-risk group. Additionally,  the genes FAM3B,
PCP4 and KCNF1 were strongly up-regulated in the mimic transfection of the four
miRNAs (Table 11). Likewise let-7a-5p these genes have not yet been associated with
the expression of let-7b-5p, miR-125a-5p and miR-615-5p so far. On the one hand
this could be an indicator that these genes are indirectly regulated by all miRNAs of
the signature. On the other hand this observation could also be an artifact generated
by the mimic transfection because it could not be validated by the transfection of
the miRNA inhibitor. Therefore, further studies have to be performed to evaluate
this observation.
In conclusion, in this thesis a seven GBM cell line panel was thoroughly characterized
in order to find a suitable cell culture model for pre-clinical research. In, a first step a
functional characterization of the prognostic 4-miRNA signature was achieved. The
generated transcriptome data after miRNA mimic and inhibitor transfection offers an
enormous  resource  for  future  studies  that  focus  on  identifying  potential  novel
targets  of  the  4-miRNAs.  Finally,  further  validation  studies  in  the  form  of
bioinformatic  target  validation  and  experimental  approaches  like  qRT-PCR  and
western blots have to be performed to ultimately validate the discovered miRNA
targets. 
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E Abstract
Glioblastoma (GBM) is the most frequent and the most aggressive type of primary
brain tumors. It is characterized by a high degree of therapy resistance, invasiveness
and  a  high  recurrence  rate  after  initial  therapy.  Currently,  the  standard  therapy
includes a combination of surgery and radiochemotherapy followed by maintenance
chemotherapy  with  TMZ.  Despite  these  aggressive  treatment  regimens,  median
overall  survival  times  are  limited  to  15-18  months  with  large  inter-individual
differences.  Current  efforts  in  GBM  research  are  aiming  at  advanced  treatment
modalities  and  implementing  personalized  treatment  options  requiring  a
stratification  of  patients  into  risk  groups  based  on  standard-of-care  therapy.
Recently, a 4-miRNA signature was discovered that allowed the stratification of GBM
patients in high- and low-risk groups based on the expression of let-7a-5p, let-7b-5p,
miR-125a-5p and miR-615-5p miRNAs. Yet, the cellular function of the miRNAs in
GBM remains  unclear.  The  aim of  this  thesis  is  to  independently  validate  the 4-
miRNA signature and to unveil the cellular role of the miRNAs by modification of the
miRNA expression and characterization of  the resulting transcriptomic changes  in
cell culture model systems. 
Therefore, seven widely used GBM cell lines (A172, LN18, LN229, T98G, U87, U138,
and U251) were analyzed for cytogenetic, phenotypic and transcriptomic properties.
Cell  line identity was confirmed by STR typing and the ploidy status and clonality
were determined by SKY karyotyping. The ploidy among the cell lines panel ranged
from near diploid to hexaploid. Additionally, subclones were present in the majority
of  the  cell  lines.  Clonogenic  survival  assays  were  performed  to  characterize  the
cellular response towards irradiation or TMZ treatment, respectively. The response
towards radiation treatment differed significantly among the cell line panel and the
resistance  towards  TMZ was mainly  reflected  by  expression  of  the MGMT gene.
Global gene expression was determined by microarray analyses to classify the cell
lines in GBM specific subtypes. The majority of the cell lines were assorted to the
mesenchymal  subtype.  LN229  and  U87-MG  cell  lines  resembled  the  classical
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subtype. Based on the cell line characterization, two cell lines (A172 and U138-MG)
were chosen for modification of the miRNA expression based on their cytogenetic
and phenotypic properties. Overexpression of the miRNA was achieved by miRNA
mimic  transfection  and  knockdown  of  the  miRNAs  was  carried  out  by  miRNA
inhibitor transfection. The resulting changes in the transcriptome were analyzed by
3’-sequencing.  Four  genes  were  identified  as  potential  targets  of  the  let-7a-5p
miRNA:  FAM3B,  PCP4,  KCNF1  and  HS3ST2.  Most  of  the  genes  were  previously
associated with cancer by promoting invasiveness of  the tumors.  This  is  the first
observation that  these genes could be potential  targets  of  the let-7a-5p miRNA.
Additionally, the LIN28A was identified being negatively regulated by the let-7a-5p
and let-7b-5p miRNAs. LIN28A was associated with poor prognosis in GBM patients
whereas high expression of the let-7 miRNAs was observed in the low-risk patient
group. Finally, the CRISPR/Cas9 system was evaluated for knockout of miRNAs but no
effect was observed.
In  conclusion,  the  present  study  provides  a  comprehensive  characterization  of  a
widely used panel of GBM cell culture models. Further, an independent validation
and cellular  characterization of  a  4-miRNA signature  in  in  vitro GBM cell  culture
models was achieved.
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F Zusammenfassung
Glioblastome  (GBM)  sind  die  häufigste  und  aggressivste  Form  von  primären
Gehirntumoren.  Das  Merkmal  von  GBM  ist  eine  hohe  Resistenz  gegenüber  den
Behandlungsmöglichkeiten sowie ein hohes Infiltrationspotential des Tumors. Für die
Behandlung von GBM wird aktuell  eine Kombination aus chirurgischer Entfernung
des Tumors mit  anschließender Strahlen- und Chemotherapie durchgeführt.  Trotz
der aggressiven Therapie liegt das klinische Überleben der Patienten im Median bei
15-18 Monaten. Das individuelle Überleben der Patienten unterliegt dabei starken
Schwankungen. Neue Therapieformen zielen deshalb auf eine personalisierte Form
der  Behandlung  ab.  Eine  Voraussetzung  für  eine  personalisierte  Therapie  ist  die
Stratifizierung von die GBM Patienten. Mit Hilfe einer 4-miRNA (let-7a-5p, let-7b-5p,
miR-125a-5p  und  miR-615-5p)  Signatur  kann  ein  Ansprechen  auf  die  derzeitige
Standardtherapie  vorhergesagt  werden.  Damit  könnte  es  möglich  werden  eine
individuelle  Anpassung  der  Behandlung  durchzuführen  und  neuartige
Therapieformen zu entwickeln. 
Das Ziel dieser Arbeit ist es, die Signatur zu validieren und die zelluläre Funktion der
miRNAs zu charakterisieren. Dafür soll die Expression der miRNAs modifiziert und die
resultierenden Änderungen im Transkriptom analysiert werden. Um ein möglichst
Tumor-nahes  Modellsystem  zu  entwickeln,  wurde  eine  Auswahl  an  sieben
etablierten GBM Zelllinien (A172, LN18, LN229, T98G, U87-MG, U138-MG und U251-
MG) charakterisiert und dabei zytogenetische, phänotypische und transkriptomische
Eigenschaften der Zelllinien zu bestimmt. Die Identität der Zelllinien wurde mit STR-
typing  bestätigt  und  das  Auftreten  von  Subklonen  mit  Hilfe  von  Karyogrammen
bestimmt. Die Ploidie der Zelllinien schwankte von diploiden bis hin zu hexaploiden
Genomen.  Das  Auftreten  von  Subklonen  konnte  in  fünf  der  sieben  Zelllinien
nachgewiesen  werden.  Die  Resistenz  der  Zelllinien  gegenüber  Bestrahlung  und
Behandlung  mit  Temozolomid  (TMZ)  wurde  über  das  klonogene  Überleben  der
Zellen bestimmt. Das Überleben der Zelllinien nach Bestrahlung schwankte stark in
den analysierten Zelllinien und die Resistenz gegenüber TMZ war hauptsächlich von
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der Expression des MGMT Gens abhängig.  Das Transkriptom der Zelllinien wurde
durch  Microarrays  charakterisiert  und  die  Zelllinien  konnten  dadurch  in  GBM
spezifische Subtypen eingeteilt werden. Mit Ausnahme von LN229 und U87-MG die
dem klassischen Subtyp  zugeordnet  werden konnten,  entstammten die  Zelllinien
dem mesenchymalen  Subtyp.  Aufgrund  der  phänotypischen  und  zytogenetischen
Charakterisierung wurden die Zelllinien A172 und U138-MG für eine Modifikation
der miRNAs ausgewählt. Eine Überexpression der miRNAs wurde durch Transfektion
von miRNA ‚mimics’  erzielt.  Um die miRNAs in den Zellen zu reduzieren, wurden
miRNA Inhibitoren eingesetzt. Die Veränderung der globalen Expression wurde mit
3’-mRNA Sequenzierung analysiert. Dabei konnten die Gene FAM3B, PCP4, KCNF1
und  HS3ST2  als  potentielle  Ziele  der  miRNA let-7a-5p  identifiziert  werden.  Diese
Gene wurde bereits  früher in Zusammenhang mit  Krebs gebracht,  indem sie  das
invasive Wachstum des Tumors verstärken. Diese Gene wurden bisher noch nicht als
potentielle Zielgene der let-7a-5p miRNA beschrieben. Das Gen LIN28A, welches in
früheren  Arbeiten  mit  einer  schlechten  Überlebensprognose  der  GBM  Patienten
beschrieben wurde, zeigte eine starke Herrunterregulation nach Zugabe der let-7a-
5p und let-7b-5p ‚mimics’. Dies könnte ein Hinweis darauf sein, warum die Patienten
mit einem niedrigeren Risikofaktor eine höhere Expression dieser miRNAs zeigen.
Zuletzt wurde das CRISPR/Cas9 System für die Herstellung von miRNA ‚knockouts’
evaluiert, dabei konnte jedoch kein knockdown der miRNAs erzielt werden.
Zusammenfassend  konnte  in  der  vorliegenden  Arbeit  eine  umfangreiche
Charakterisierung von weit verbreiteten GBM Zellkultur Modellen erreicht werden.
Zudem wurde eine prognostische 4-miRNA Signatur validiert und in GBM Zelllinien
funktionell charakterisiert.
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